

CERM Trial Protocol

Short title	The CERM trial
Full title	Chronic Endometritis and Recurrent Miscarriage - The CERM trial
IRAS number	251756
EudraCT number	2019-000585-38
ISRCTN number	23947730
Sponsor	University Hospitals Coventry and Warwickshire NHS Trust
Sponsor reference	SQ411218
Funder	NIHR - Efficacy and Mechanism Evaluation (EME) Programme
Funder reference	17/60/22
REC	North West - Haydock Research Ethics Committee
REC reference	19/NW/0462
REC approval date	20/08/2019
MHRA approval date	20/08/2019
Trial start date	01/06/2019
Trial end date	30/04/2024
Version number	V9.0
Version dated	08 Sep 2023
Protocol stage	Final

Protocol Amendments

Amendment No.	Date of Amendment	Date of Approval
1 (V3.0 19 Dec 2019)	20/12/2019	10/01/2020
2 (V4.0 30 Jan 2020)	15/05/2020	22/06/2020
3 (V5.0 22 Jul 2020)	12/08/2020	07/09/2020
4 (V6.0 08 Feb 2021)	05/03/2021	12/04/2021
5 (V7.0 22 Mar 2021)	29/04/2021	29/04/2021
6 (V8.0 03 May 2022)	21/06/2022	19/07/2022
7 (V9.0 08 Sep 2022)	TBC	TBC

DoH Disclaimer - This project (project reference 17/60/22) is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership. The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NIHR or the Department of Health and Social Care.



SIGNATURE PAGE

The undersigned confirm that the following protocol has been agreed and accepted and that the Chief Investigator agrees to conduct the trial in compliance with the approved protocol and will adhere to the principles outlined in the Medicines for Human Use (Clinical Trials Regulations 2004 (SI 2004/1031), amended regulations (SI 2006/199828) and any subsequent amendments of the clinical trial regulations, GCP guidelines, the Sponsor's and Warwick SOPs and other regulatory requirements as amended.

I also confirm that I will make the findings of the trial publicly available through publication or other dissemination tools without any unnecessary delay and that an honest accurate and transparent account of the trial will be given; and that any discrepancies from the trial as planned in this protocol will be explained.

For and on behalf of the trial Sponsor:

Sponsor, Research Operations Manager

Signature:

Date:

Approved electronically

Name (please print):

Ceri Jones

Chief Investigator:

Signature:

Date:

Signed electronically via Q-Pulse

Name (please print):

Prof Siobhan Quenby

Statistician:

Signature:

Date:

Signed electronically via Q-Pulse

Name (please print):

George Bouliotis

Table 1 - Trial team contacts

Name	Role [Position(s)]	Organisation	Contact details
Siobhan Quenby Professor of Obstetrics	Chief Investigator	Clinical Sciences Research Laboratories University Hospitals Coventry and Warwickshire, Clifford Bridge Road Coventry, CV2 2DX	Email: s.quenby@warwick.ac.uk Tel: +44 (0)24 7696 4000 bleep 4387 Mobile: 07873416716
Phillip Bennett Director of the Institute of Reproductive and Developmental Biology	Expert - miscarriage / microbiome	Faculty of Medicine Imperial College London Institute for Reproductive and Developmental Biology, Hammersmith Hospital Campus, Du Cane Road London, W12 0NN	Email: pbennett@imperial.ac.uk Tel: +44 (0)20 759 42176
George Bouliotis Associate Professor / Principal Statistician	Trial Statistician	Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Campus Coventry, CV4 7AL	Email: georgios.bouliotis@warwick.ac.uk Tel: +44 (0)24 7655 0056
Jan Brosens Professor of Obstetrics & Gynaecology	Expert - miscarriage mechanism	Clinical Sciences Research Laboratories University Hospitals Coventry and Warwickshire, Clifford Bridge Road Coventry, CV2 2DX	Email: j.j.brosens@warwick.ac.uk Tel: +44 (0)24 7696 8704
Arri Coomarasamy Director of Tommy's National Centre for Miscarriage Research	Expert - clinical trials and miscarriage	Academic Unit Birmingham Women's Hospital Foundation Trust Mindelsohn Way, Edgbaston Birmingham, B15 2TG	Email: a.coomarasamy@bham.ac.uk Tel: +44 (0)12 14721377

Simon Gates Professor of Clinical Trials	Statistical advisor	Cancer Research UK Clinical Trials Unit Institute of Cancer and Genomic Sciences University of Birmingham Edgbaston, Birmingham, B15 2TT	Email: s.gates@bham.ac.uk Tel: +44 (0)12 1415 9179
Amy Jackson Co-founder of the Lily Mae Foundation	PPI advisor	Lily Mae Foundation First Floor The Annex, Fernhill Court Balsall Street East, Balsall Common West Midlands, CV7 7FR	Email: info@lilymaefoundation.org Tel: +44 (0)16 7653 5716
Ceri Jones Head of R&D	Sponsor	Research & Development, 4th Floor Rotunda, ADA40007, University Hospitals Coventry and Warwickshire Clifford Bridge Road Coventry, CV2 2DX	Email: ceri.jones@uhcw.nhs.uk Tel: +44 (0)24 7696 5031 Ext: 25031
Research Operations Manager	Sponsor	Research & Development, 4th Floor Rotunda, ADA40007, University Hospitals Coventry and Warwickshire Clifford Bridge Road Coventry, CV2 2DX	Email: ResearchSponsorship@uhcw.nhs.uk
Mojid Khan Pharmacist	Pharmacist Advisor	University Hospitals Coventry & Warwickshire, Clifford Bridge Road Coventry, CV2 2DX	Email: mohammed.khan2@uhcw.nhs.uk Tel: +44 (0)24 7696 4000 bleep 2847
David MacIntyre Senior Lecturer in Reproductive Systems Medicine	Expert - microbiome	Imperial College London Institute of Reproductive and Developmental Biology Department of Surgery and Cancer Imperial College, Hammersmith Hospital Campus, DuCane Road London, W12 ONN	Email: d.macintyre@imperial.ac.uk Tel: +44 (0)20 7594 2195

Joshua Odendaal Clinical Research Fellow	Screening biopsies	University Hospitals Coventry and Warwickshire Clifford Bridge Road Coventry, CV2 2DX	Email: joshua.odendaal@warwick.ac.uk Tel: +44 (0)24 7696 8702
Kimberley Stewart Senior Project Manager	Trial management	Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Campus Coventry, CV4 7AL	Email: kimberley.stewart@warwick.ac.uk
Martin Underwood Professor of Primary Care Research	WCTU Lead	Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Campus Coventry, CV4 7AL	Email: m.underwood@warwick.ac.uk Tel: +44 (0)24 7657 4664 Mob: +44 (0) 7881 267525
Adrian Willis Programming	WCTU Programming Team Manager	Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Campus Coventry, CV4 7AL	Email: adrian.willis@warwick.ac.uk Tel: +44 (0)24 7615 0712
WCTU QA Team Quality Assurance	Quality Assurance	Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Campus Coventry, CV4 7AL	Email: wctuqa@warwick.ac.uk

Table 2 - Trial Steering Committee (TSC)

Name / TSC role	Position(s)	Organisation / address	Contact details
Andrew Horne Chair	Professor of Gynaecology and Reproductive Sciences of Gynaecology and Reproductive Sciences	MRC Centre for Reproductive Health University of Edinburgh The Queen's Medical Research Institute 47 Little France Crescent Edinburgh, EH16 4TJ	Email: andrew.horne@ed.ac.uk Tel: +44 (0)131 242 6988 (P.A. Ms Jackie Young)
Jim Thornton Clinical Expert	Professor of obstetrics and gynaecology	Faculty of Medicine and Health Sciences Medical School University of Nottingham Nottingham, NG7 2UH	Email: jim.thornton@nottingham.ac.uk Tel: + 44 (0)11 5823 1889 (work)
Sally Kerry Medical Statistician	Reader in Medical Statistics	Pragmatic Clinical Trials Unit Centre for Primary Care and Public Health Blizard Institute Yvonne Carter Building 58 Turner Street London, E1 2AB	Email: s.m.kerry@qmul.ac.uk Tel: + 44 (0)20 7882 7208 (work)
Rachel Roberts Public Member	Senior Research Manager - Tommy's	Nicholas House 3 Laurence Pountney Hill London, EC4R 0BB	Email: rroberts@tommys.org
Ceri Jones (or representative) Sponsor observer	Head of Research and Development	Research & Development, 4th Floor Rotunda, ADA40007, University Hospitals Coventry & Warwickshire Clifford Bridge Road Coventry, CV2 2DX	Email: ceri.jones@uhcw.nhs.uk Tel: +44 (0)24 7696 5031 Ext: 25031

George Bouliotis Medical Statistician	Associate Professor / Principal Statistician	Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Campus Coventry, CV4 7AL	Email: georgios.bouliotis@warwick.ac.uk Tel: +44 (0)24 7655 0056
Siobhan Quenby Chief Investigator Observer	Professor of Obstetrics	Clinical Sciences Research Laboratories University Hospitals Coventry and Warwickshire Clifford Bridge Road Coventry, CV2 2DX	Email: s.quenby@warwick.ac.uk Tel: +44 (0)24 76964000 bleep 4387 Mobile: +44 (0) 7873 416716

Table 3 - Data Monitoring Committee (DMC)

Name / DMC role	Position(s)	Organisation	Contact details
Alex McConnachie Chair / Statistician	Assistant Director of Biostatistics	Institute of Health and Wellbeing College of Medical, Veterinary and Life Sciences Robertson Centre for Biostatistics Boyd Orr Building, Level 11 University of Glasgow Glasgow, G12 8QQ	Email: alex.mcconnachie@glasgow.ac.uk Tel: +44 (0)14 1330 4744
Sharon Cameron Clinical expert member	Consultant and Professor Sexual and Reproductive Health	Chalmers Centre NHS Lothian 2a Chalmers Street Edinburgh EH3 9ES	Email: sharon.cameron@ed.ac.uk Tel: +44 (0)131 536 2091
Mary Stephenson Clinical expert member	Professor of Obstetrics and Gynecology	Department of Obstetrics and Gynecology University of Illinois at Chicago 820 South Woos Street (MC 808) Chicago, IL 60612 USA	Email: msteph@uic.edu Tel: (312) 996-7006
George Bouliotis Observer	Associate Professor / Principal Statistician	Warwick Clinical Trials Unit The University of Warwick Gibbet Hill Campus Coventry, CV4 7AL	Email: georgios.bouliotis@warwick.ac.uk Tel: +44 (0)24 7655 0056

Table 4 –Trial Management Team Information

Service	Contact details
Trial Coordinating Centre:	CERM Trial Team, Warwick Clinical Trials Unit, The University of Warwick, Gibbet Hill Campus, Coventry, CV4 7AL
General enquires:	<p>Telephone: Tel: +44 (0)24 7657 5194</p> <p>Trial email: cerm@warwick.ac.uk</p> <p>Trial website: https://warwick.ac.uk/cerm</p>

Contents

SIGNATURE PAGE.....	2
Table 1 - Trial team contacts	3
Table 2 - Trial Steering Committee (TSC)	6
Table 3 - Data Monitoring Committee (DMC)	8
Table 4 –Trial Management Team Information	9
TRIAL SUMMARY	15
Table 5 – CERM Schedule of Events.....	18
Table 6 – Trial tasks and Milestones	21
ABBREVIATIONS / GLOSSARY	22
1. INTRODUCTION	24
1.1 Background	24
1.1.1 Epidemiology and burden of the condition	24
1.1.2 Chronic Endometritis and Recurrent Miscarriage	24
1.1.3 Diagnosing Chronic Endometritis	24
1.1.4 Chronic Endometritis and the Microbiome	24
1.1.5 Evidence that CE is a treatable cause of miscarriage	25
1.1.6 Evidence of endometrial microbiome dysbiosis in CE	25
1.1.7 Evidence of the impact of CE on endometrial function	26
1.1.8 Evidence of efficacy of doxycycline treatment	26
1.2 Proposed trial	26
1.3 Target population	27
1.4 Chronic Endometritis Diagnosis.....	27
1.5 Treatment	27
2. RATIONALE.....	28
2.1 Aims and hypothesis.....	28
2.2 Justification.....	28
2.3 Assessment and management of risk	28
2.3.1 Risk of Pregnancy.....	28
3. OBJECTIVES AND OUTCOME MEASURES.....	30
3.1 Primary objective	30
3.1.1 Primary outcome measure	30
3.2 Secondary objectives	30
3.2.1 Secondary Outcome measures:.....	30
3.3 Exploratory Objectives.....	31
3.3.1 Exploratory Outcome measures	31
4. TRIAL DESIGN.....	32
5. TRIAL SETTING	34

5.1 Site requirements:	34
5.2 Site Initiation	34
5.3 Site staff Training	34
5.3.1 Principal Investigator (PI)	34
5.3.2 Research Team at site	35
5.3.3 Clinicians confirming eligibility and consenting to the trial	35
5.3.4 Clinicians performing endometrial biopsies and vaginal, endometrial and cervical swabs	35
6. ELIGIBILITY CRITERIA	36
6.1 Inclusion criteria – biopsy preparation-pre-eligibility	36
6.2 Inclusion criteria - screening biopsy	36
6.3 Exclusion criteria – screening biopsy	37
Table 7 - excipients of doxycycline/placebo capsules	38
6.4 Inclusion criteria - RCT	38
6.5 Exclusion criteria – RCT	38
6.5 CERM B Exclusion (repeat endometrial biopsy and vaginal, cervical and endometrial swabs)	39
7. TRIAL PROCEDURE	40
Figure 2 – Pathways to recruitment	40
7.1 Patient Identification	41
7.1.1 Women on the Tommy’s ‘Recurrent Miscarriage’ database	41
7.1.2 Women referred to a recurrent miscarriage clinic or early pregnancy unit (EPU)	41
7.1.4 Screening Log	42
7.2 Biopsy Preparation	42
7.3 Screening	42
Table 8 – trial cycles	42
7.3.1 Consent for Screening and RCT	43
7.3.2 Consent CERM B	43
7.4 Registration – screening	43
7.5 Biopsy results	44
7.6 Randomisation	44
7.6.1 Verbal Reaffirmation of RCT Consent	44
7.6.2 Verbal Reaffirmation of RCT CERM B Consent	45
7.7 Randomisation – Randomised Controlled Trial	45
7.8 Blinding	46
7.9 Follow up for women who screen negative for CE	48
7.10 Patient information and consent review and guidance	48
7.10.1 Consent overview	48
7.11 End of trial	48
8. TRIAL TREATMENTS	50

8.1 Name and description of investigational medicinal product(s)	50
8.2 Regulatory status of the drug	50
8.3 Product Characteristics	50
8.4 Drug storage and supply	50
8.4.1 Temperature monitoring and excursions	51
8.4.2 Ordering	51
8.4.3 Shipment	51
8.4.4 Receipt	51
8.4.5 Distribution	52
8.4.6 Return	52
8.4.7 Product recall	52
8.4.8 Destruction	52
8.5 Preparation and labelling of Investigational Medicinal Product	52
8.5.1 Prescribing and Dispensing	52
8.5.2 Accountability, Reconciliation and Destruction	53
8.6 Dosage schedules	53
8.6.1 Dose	53
8.6.2 Administration	53
8.6.4 Precautions in renal failure	53
8.6.5 Precautions in hepatic failure	54
8.6.6 Precautions in haematological toxicity	54
8.7 Dosage modifications	54
8.8 Known drug reactions and interaction with other therapies	55
Table 9 - medications known to interact with doxycycline and prohibited from being taken during the intervention	55
8.9 Concomitant medication	55
8.10 Trial restrictions	55
8.11 Assessment of compliance with treatment	56
9. TRIAL ASSESSMENTS	57
9.1 Screening and Registration	57
9.2 Screening	57
9.3 Randomised Controlled Trial	57
9.4 Treatment completion	58
9.5 Pregnancy review	59
9.5.1 Women who do not have CE and are not randomised	59
9.5.2 Women with CE who are randomised	59
9.6 12 week assessment– standard practice 12 week ultrasound scan (+/- 2weeks)*	60
9.7 20 – 24 week assessment – standard practice 20-24 week ultrasound scan (+/- 2 weeks)*	60
9.8 Additional visits/ultrasound scans as per standard practice*	60

9.9 End of pregnancy assessment or follow-up(6 – 8 weeks post end of pregnancy).....	60
9.10 Payment.....	61
10. PHARMACOVIGILANCE	62
10.1 Definitions.....	62
10.2 Operational definitions for AEs/SAEs	63
Table 10 – Events collected via CRF exempt from AE/SAE reporting	63
Table 11 – Adverse Events exempt from SAE reporting but still recorded as AEs	64
10.3 Recording and reporting of AEs SAEs, SARs AND SUSARs	64
10.3.1 Recording of Adverse Events	64
10.3.2 Reporting SAEs and SUSARs.....	65
Table 12 – SAE Causal relationship.....	65
10.4 Responsibilities	66
10.5 Notification of deaths	68
10.6 Reporting urgent safety measures	68
10.7 Development safety update reports.....	68
11. TISSUE SAMPLES	69
11.1 Endometrial Biopsies	69
11.1.2 Analysis of endometrial biopsies	69
11.1.3 Results of endometrial biopsy samples	70
11.2 Microbial swabs	70
11.2.1 Analysis of the microbiome	70
12. STATISTICS AND DATA ANALYSIS	71
12.1 Sample size	71
12.1.2 Sample size – screening trial.....	71
12.1.3 Sample size - randomised controlled trial	71
12.2 Stratification	72
12.3 Statistical analysis.....	72
12.3.1 Interim analysis.....	73
12.3.2 Final analysis	73
13. DATA MANAGEMENT	74
13.1 Data collection tools and source document identification.....	74
13.1.1 Database	74
13.1.2 eCRF completion.....	74
13.1.3 Missing data.....	74
13.1.4 Timelines for eCRF completion	74
13.1.5 Data quality.....	75
13.1.6 Post randomisation withdrawals and exclusions.....	75
13.2 Data handling and record keeping.....	75

13.3 Access to data	75
13.4 Data archiving	76
14. TRIAL OVERSIGHT	77
14.1 Role and responsibilities of the Sponsor	77
14.1.1 Indemnity	77
14.2 Role and responsibilities of the Funder	77
14.3 Trial management arrangements	77
14.3.1 Trial Management Group	77
14.3.2 Trial Steering Committee	78
14.3.3 Data Monitoring Committee	78
14.3.4 Investigator meetings	78
14.3.5 Essential documentation	78
14.3.6 Warwick CTU CERM trial team	78
15.4 Trial registration	79
15. MONITORING, AUDIT & INSPECTION	80
15.1 Training	80
15.2 Quality assurance	80
15.3 Visits to sites	80
16. ETHICAL AND REGULATORY CONSIDERATIONS	82
16.1 Ethical approval and research governance	82
16.2 Ethical considerations for women participating in CERM	82
16.3 Notification of Serious Breaches to GCP and/or the protocol	83
16.4 Patient and Public Involvement	83
16.4.1 The Lily-Mae Foundation	83
16.4.2 The Tommy's Charity	84
17. DISSEMINATION AND PUBLICATION	85
18. REFERENCES	86

TABLE OF FIGURES**PAGE NUMBER**

Figure 1	CERM Process Flow Chart	18
Figure 2	Pathways to recruitment	40
Figure 3	Emergency Unblinding procedure	47
Figure 4	CERM consent overview	48
Figure 5	CERM participant journey	82


TRIAL SUMMARY

Item	Details
Trial title	Chronic Endometritis and Recurrent Miscarriage - The CERM trial
Short title	The CERM trial
Trial aim	The aim of this trial is to determine if doxycycline administered prior to conception improves pregnancy outcome in women with recurrent miscarriage associated with chronic endometritis (CE) and explore the mechanisms by which it could prevent miscarriage.
Clinical phase	Phase II/III trial
Trial design	A prospective, multi-centre, randomised, double blind adaptive designed trial, comparing a course of doxycycline against placebo.
Trial participants	Women who have experienced two or more consecutive first trimester miscarriages (≤ 14 weeks gestation), who are aged ≥ 18 to < 42 .
Trial arms	Intervention arm – 100mg of doxycycline twice daily for 14 days. Control arm – placebo twice daily for 14 days.
Planned sample size	Sample size for endometrial biopsy $N=3,062$. Sample size for women who screen positive for CE and wish to enter the randomised controlled trial $n=1,500$, $n=750$ in the intervention arm (doxycycline) and $n=750$ in the control arm (placebo). This trial will use adaptive design methodology so the trial can stop early, with fewer than 1500 patients randomised, in the case of better than expected efficacy or in the case of futility.
Planned trial period	48 months* *Final date of trial follow-up agreed as 31 st October 2023
Treatment duration	Women who screen positive for CE will take the doxycycline/placebo for 14 days.
Follow-up duration	Women without CE 1. All women will remain in the trial until eight weeks post-delivery, or pregnancy demise, or for 12 months after result of the biopsy, or the trial ends. Women with CE recruited into randomised control trial 2. If women have a pregnancy demise before 24 weeks gestation they will remain within the trial and successive pregnancies recorded and monitored as part of trial outcomes. 3. All women will remain in the trial until eight weeks post-delivery or pregnancy outcome (if gestation $\geq 24 + 0$ weeks) or the trial ends.

Planned recruitment start date	01/10/2019	Planned trial end date	30/04/2024
	Objectives	Outcome Measures	
Primary	To find out if doxycycline given prior to conception improves the number of on-going pregnancies and total live births in women with recurrent miscarriage associated with chronic endometritis?	Total live births plus on-going pregnancies at $\geq 24 + 0$ weeks gestation at the end of the trial in first or subsequent pregnancy.	
Secondary	<p>To find out if doxycycline treatment improves CE?</p> <p>To examine the separate effects of doxycycline on conception, early miscarriage, and late miscarriage. In addition assess the mediation effect of each of these, on the primary outcome, with treatment effect as a covariate.</p>	<p>Density of CD138+ cells in the endometrium before and after treatment with doxycycline/placebo.</p> <p>On-going viable pregnancy at 12 weeks</p> <p>Time to first conception</p> <p>Anticipated time to first live birth</p> <p>The proportion of women with a live birth $\geq 24 + 0$ weeks of gestation in their first pregnancy after randomisation.</p> <p>Pregnancy complications</p> <p>Early pregnancy complications</p> <p>Type of miscarriage</p> <p>Miscarriage, on-going pregnancy and live births per patient in women excluded from randomisation by having low CD138+ cell scores and those randomised to placebo.</p>	
Exploratory	<p>To find out if doxycycline treatment changes Lactobacillus-deplete microbiota to a Lactobacillus-dominated microbiota?</p> <p>To find out if doxycycline treatment, improves the differentiation potential and colony-forming activity of endometrial stromal cells?</p> <p>To find out if CE is related to heightened senescence of endometrial stromal cells?</p>	<p>Evaluate changes of Lactobacillus-deplete microbiota to a Lactobacillus-dominated microbiota after treatment with doxycycline/placebo.</p> <p>Assess changes in differentiation potential and colony-forming activity of endometrial stromal cells after treatment with doxycycline/placebo.</p> <p>Assess senescence associated β Galactosidase activity in patients with CE.</p>	

IMP	Doxycycline, an antibiotic available on prescription and used for the treatment of infections caused by bacteria and parasites.	
Formulation, dose, route of administration	Doxycycline Capsules Dose: 100 mg twice a day Route: oral Duration: 14 days	Placebo Capsules Dose: twice a day Route: oral Duration: 14 days
Key words	Chronic Endometritis; Recurrent Miscarriage; Microbiome; RCT; Doxycycline.	

Figure 1 – CERM Process Flowchart



* The end of overall trial follow-up may truncate an individual participant's follow-up to a maximum of month 12.

Table 5 – CERM Schedule of Events

Observations/Procedures	Biopsy Preparation	Screening (Registration)		Randomisation		Post-treatment	Pregnancy	Main Trial Assessments			
	Tommy's NET/RM Clinic/EPU	Pre-reg	Post-reg	CE + women		Treatment completion	Pregnancy Review	12 (+/- 2) weeks ⁷	20 -24 weeks ⁷	Extra Scan ⁶	End of pregnancy (8 wks)
CEM letter and PIS posted/emailed	●										
Telephone contact – Trial Participation	●										
Pre-screening eligibility	●										
Verbal Consent ¹	●										
Biopsy preparation kit sent/given	●					● ³					
Patient Demographics		●									
BMI (Height/weight)		●									
Smoking history		●									
Medical History		●									
Concomitant medication review		●		●							
Obstetric History		●									
Pregnancy History		●									
Review Eligibility		●		●							
Pregnancy Test		●		●		● ³					
Contraception use review		●		●		●					
Period Review		●		●		● ³					
Written Consent CERM A ² or CERM B ^{2,3}		●									
Registration		●									
Endometrial Biopsy			●			● ³					
Swabs – CERM B Only ³			● ³			● ³					
Provide pregnancy testing kit			●								
Inform patient of CE results			●	●							
Adverse event review			●	●		●	●				
Verbal reaffirmation consent ⁴				● ⁴							
Randomisation				●							
Treatment instructions					●						

Dispense medication					●						
Treatment compliance check						●					
Contact patient at 3, 6, 12 and, if randomised, 24 months to determine pregnancy							●				
Pregnancy confirmation								●	● ⁵		
Ultrasound								●	●	● ⁶	
Concomitant medication review (on trial)						●		●	●	●	●
Pregnancy complications ⁵								●	●	●	●
Pregnancy outcome assessments											●
End of Trial Follow-up for randomised participants who have conceived by month 24			●								

¹ Verbal consent must be given (and documented) prior to biopsy kits being given/sent

² Written informed consent must be given prior to any trial specific procedures taking place.

³ CERM B patients only (UHCW ONLY)

⁴ Verbal consent must be given (and documented) prior to randomisation

⁵ If appropriate

⁶ Only if clinically indicated

⁷ Timing of visit as per local hospital policy

Table 6 – Trial tasks and Milestones

Tasks	Time period (months)
Trial preparation: approvals (ethics, R&D), research governance (oversight committees (TMG, TSC and DMC), staff training), develop project management plan, registration, contracting, new appointments, send capacity and capability questionnaires to trial sites, trial administration processes (participant files, master file), trial branding, and social media for general use throughout the trial.	Apr 2019 – May 2019 (pre-start)
Trial set-up: liaise with trial pilot sites, track R&D, develop randomisation service, develop data collection process, prepare training manual, print recruitment information (introduction letter, participant information sheet, participant information leaflet, posters) and prepare site-initiation materials.	June 2019 – December 2019
Site set-up: Initially ten sites; four per month (not including the first and last months, August and December).	June 2019 – August 2022
Participant recruitment: n=1,500 randomised	December 2019 – October 2022
Feasibility: after six months of recruitment when >68 participants have been recruited.	When applicable
Follow-up: birth.	December 2021 – October 2023
Three Planned Interim analyses: when 100, 300 and 900 women have reached 28 weeks post randomisation.	When applicable
Data analysis	November 2023 – January 2024
Dissemination: final report, publications, press release, social media, newsletter and a dissemination event.	From April 2024

ABBREVIATIONS / GLOSSARY

Abbreviation	Description
AE	Adverse Event
AEPU	Association of Early Pregnancy Units
ART	Assisted Reproduction Techniques
CE	Chronic Endometritis
CI	Confidence Interval
CONSORT	Consolidated Standards Of Reporting Trials
CRF	Case Report Form
CRL	Crown-Rump Length
CSRL	Clinical Sciences Research Laboratories
CTA	Clinical Trial Authorisation
CTCAE	Common Terminology Criteria for Adverse Events
CTIMP	Clinical Trial of an Investigational Medicinal Products
DMC	Data Monitoring Committee
EMC	Electronic Medicines Compendium
EME	Efficacy and Mechanism Evaluation
EnSCs	Endometrial Stromal Cells
EPU	Early Pregnancy Unit
EudraCT	European drug regulatory affairs Clinical Trials
ESHRE	European Society of Human Reproduction and Embryology
FBC	Full Blood Count
GCP	Good Clinical Practice
GDPR	General Data Protection Regulation
GMP	Good Manufacturing Practice
GP	General Practitioner
H&E	Haematoxylin and Eosin
HRA	Health Research Authority
IHC	Immunohistochemistry
IMP	Investigational Medicinal Product
IRAS	Integrated Research Application System
ISF	Investigator Site File
ISRCTN	International Standard Randomised Controlled Trial Number
ITT	Intension To Treat

IWRS	Interactive Web Response Systems
LEfSe	Linear discriminant analysis effect size
LFT	Liver function tests
LTFU	Lost To Follow Up
MHRA	Medicine and Healthcare Products Regulatory Agency
MSCs	Mesenchymal Stem-like Cells
NGS	Next Generation Sequencing
NHS	National Health Service
NICE	The National Institute for Health Care Excellence
QP	Qualified Person
PI	Principal Investigator
PIS	Participant Information Sheet
PSF	Pharmacy Site File
PPI	Patient and Public Involvement
R&D	Research and Development
RCOG	The Royal College of Obstetricians and Gynaecologists
RCT	Randomised Controlled Trial
RM	Recurrent Miscarriage
SAE	Serious Adverse Event
SD	Standard Deviation
SIV	Site Initiation Visit
SmPC	Summary of Product Characteristics
SOP	Standard Operating Procedure
STAMP	Statistical Analysis of Taxonomic and Functional Profiles
SUSAR	Suspected Unexpected Serious Adverse Reaction
TMG	Trial Management Group
TSC	Trial Steering Committee
UHCW	University Hospitals Coventry and Warwickshire NHS trust
uNK	uterine Natural Killer
WCTU	Warwick Clinical Trials Unit

1. INTRODUCTION

The purpose of this trial is to find out if a short course of antibiotics will treat chronic endometritis and reduce miscarriage in women who have experienced two or more consecutive miscarriages. Endometritis is an inflammation of the endometrium (lining of the womb). The group of microorganisms that live in our bodies is called the microbiome and if there is an imbalance of the microbiome (dysbiosis) in the reproductive tract this may cause inflammation of the endometrium. The endometrium is important for implantation of the ovum (egg and sperm) and to support the fetus as it develops. Endometritis may disrupt implantation and lead to miscarriage. Endometritis has been linked to miscarriage and it is suggested that reducing the inflammation, with a course of antibiotics, will reduce miscarriages.

1.1 Background

1.1.1 Epidemiology and burden of the condition

Recurrent miscarriage (RM) causes considerable distress and psychological morbidity for women and their partners. The vast-majority of couples receive supportive care only, as few treatments have been shown to prevent miscarriage. The patient-led James Lind Alliance priority setting partnership has identified '*effective interventions to prevent miscarriage*' as a number one research priority.¹

1.1.2 Chronic Endometritis and Recurrent Miscarriage

A healthy endometrium is important for successful implantation and support of the developing fetus. The bacteria that colonise the endometrium and vagina, known as the microbiome, play an important role in the endometrial health. Dysbiosis, an imbalance of the microbiome may cause inflammation of the endometrium, known as Chronic Endometritis (CE) and lead to miscarriage. Antibiotics can reduce this inflammation; although this treatment is available at private clinics and in some European countries, there is no robust evidence to support this approach and the effect of antibiotics on the microbiome is unclear.

1.1.3 Diagnosing Chronic Endometritis

Initially, the diagnosis of chronic endometritis was based on Haematoxylin and Eosin (H&E) staining of tissue sections,² but the identification of plasma cells on morphology alone is cumbersome and associated with substantial significant inter-observer variation. During differentiation, plasma cells acquire expression of CD138 (syndecan-1). Immunohistochemistry (IHC) with antibodies to CD138 reliably identify plasma cells³ with increased sensitivity,⁴ increased concordance between pathologists,⁵ and reduced inter- or intra-observer variability when compared to H&E staining.⁶ Thus, IHC is now the method of choice for identification of plasma cells. Plasma cells are not usually present in high numbers in normal endometrium.

1.1.4 Chronic Endometritis and the Microbiome

CE is thought to be caused by the presence of an array of microorganisms and a lack of lactobacilli in the endometrium, an imbalance termed dysbiosis.⁷⁻¹¹ Three separate studies reported that a two-week course of the antibiotic doxycycline 'cured' CE in over 90% of cases.⁹

¹²⁻¹⁴ Additionally, non-randomised, observational studies suggest that treating CE with doxycycline prevents miscarriage.^{9 12 15 16}

1.1.5 Evidence that CE is a treatable cause of miscarriage

Our systematic review did not identify any RCTs of the use of antibiotics for the treatment of CE or for the prevention of miscarriage. Meta-synthesis of non-randomised studies of women with reproductive failure, from any cause, revealed that the prevalence of CE varies between 9%-57%; reflecting the different methods and criteria used for diagnosis. Our analysis of live births in non-randomised cohort studies in women who conceived following a diagnosis of CE indicated that:

1. The live births versus miscarriages in treated versus untreated CE could not adequately be assessed as the studies were too small to reliably identify important differences.^{15 16}
2. The live birth following treatment of CE was similar to that of patients without CE. These data imply that treating CE improves the live birth rate to that of women with no CE. However, these studies were small, single centre, non-randomised and used varying treatment regimens.
3. There are more live births in women treated for CE which resolved than in those in whom the CE persisted after treatment again suggesting a positive effect of treatment but in observational studies only.

1.1.6 Evidence of endometrial microbiome dysbiosis in CE

Although the pathophysiology of CE is poorly understood, the presence of plasma cells is thought to reflect either chronic infection or chronic inflammation.² It has been suggested that the presence of plasma cells reflects an immune response to pathogens within the uterine cavity that ascended from the lower genital tract.¹⁷ Several studies have sought to identify and characterise these microorganisms; however, recent application of culture-independent sequencing approaches demonstrated that the endometrium is not a sterile environment, as previously believed.¹⁸ Instead the endometrium harbours its own unique microbiome.¹⁹ This has been replicated in other tissues previously believed to be sterile, including the lung, placenta²⁰ and lower urinary tract.²¹ As such the identification of organisms may not represent pathological colonisation but rather a healthy balance of microorganisms that are essential for the optimal function of the endometrium. Dysbiosis of the endometrial microbiome may account for plasma cell infiltration in CE. Next Generation Sequencing (NGS) of bacterial 16S ribosomal RNA genes has been undertaken to characterise the endometrial microbiome. Like the vaginal microbiome, the endometrium is typically dominated by *Lactobacillus spp.*^{22 23} The endometrial microbiota of patients undergoing Assisted Reproduction Techniques (ART) was found to be similar to that of the vagina.^{8 24} However, differences in the vaginal and endometrial microbiome imply they are not merely a continuation of each other, but distinct environments with a similar yet unique microbiome.²⁴ Compared to a normal endometrial microbiome (>90% *Lactobacillus spp.*), *Lactobacillus spp.* depletion (<90%) is associated with significantly poorer ART outcomes implantation, 60% v 33% p=0.03, on-going pregnancy, 59% v 13% p=0.02 and live birth rates, 58% v 7% p=0.002).²⁴

A comparison of the microbial profile in recurrent implantation failure patients demonstrated that those with CE had a higher detection rate of specific species, including *Corynebacterium*

(RR, 19.60) and *Mycoplasma hominis* (RR, 5.04), compared to those without CE.^{9 25} Another trial focussing on endometrial polyps reported that the endometrial microbiome was more diverse in CE confirmed by IHC.⁸ Further, using the less sensitive culture techniques, organisms were detected in 73% of CE cases,⁷ *Ureaplasma urealyticum* in 10% and *Chlamydia trachomatis* was 2.7%.⁷ Using sequencing techniques the presence of these organisms detected by culture was associated with a reduction in *Lactobacillus* spp., indicative of dysbiosis¹⁰ and poor pregnancy outcomes.¹¹

1.1.7 Evidence of the impact of CE on endometrial function

Our literature search identified no studies on how CE impacts on endometrial function. RM is associated with inadequate preparation of the endometrium for pregnancy, a process termed decidualisation.²⁶ Because of menstruation, decidualisation is a reiterative process, linked to cyclic activation of mesenchymal stem-like cells (MSCs) and their subsequent differentiation into mature stromal cells in regenerating endometrium.^{26 27} Clinically, endometrial MSC deficiency,²⁷ heightened cellular senescence, prolonged inflammation^{26 28} and impaired decidualisation potential of endometrial stromal cells²⁹ are strongly linked to RM, but whether or not these defects are caused by CE is not known.

1.1.8 Evidence of efficacy of doxycycline treatment

The most frequently used antibiotic regime in published studies is doxycycline (100mg twice daily for 14 days). Based on analysis of repeat endometrial biopsies, a single course of doxycycline was reported to 'cure' histologically defined CE in 92%,⁹ 94%,¹² 75%,¹³ and 70%¹⁴ of patients. Following doxycycline treatment, changes to the endometrial microbiome have been identified. Notably, the detection rates of *Corynebacterium*, *Enterococcus*, *Escherichia coli*, *Streptococcus agalactiae*, *Ureaplasma urealyticum* and *Ureaplasma parvum* were significantly lower following antibiotic treatment.⁹ This reduction in pathogenic microorganisms was associated both with a significant increase in *Lactobacillus* spp, the major resident species within the uterine cavity³⁰ and a reduction in the number of plasma cells within the endometrial stromal compartment.⁹ This suggests a shift towards a normal microbiota following doxycycline treatment. Importantly, no trial to date reported on the persistence of CE on repeat biopsies in non-treated women. We found that ≥ 12 CD138+ cells/mm² persisted in only 78% of untreated women when biopsied again after two or more cycles (n=32).

These observations suggest that CE may resolve spontaneously, or be intermittent, in some women but persists in others. Further, in addition, to its antibacterial properties, doxycycline has a well-documented anti-inflammatory effect,³¹ raising the possibility that it is useful for the treatment of CE not associated with endometrial symbiosis.

1.2 Proposed trial

A prospective, multi-centre, randomised, double blind adaptive designed trial, comparing a pre-conception 14 day course of doxycycline to placebo in up to 1500 women with recurrent miscarriage associated with chronic endometritis.

1.3 Target population

Women aged between ≥ 18 to < 42 at registration who have experienced two or more consecutive first trimester miscarriages.

For the purpose of the trial a first trimester miscarriage will be classed as an intrauterine pregnancy ≤ 14 weeks gestation.

Participants cannot have had a live birth/still birth/termination in between or after their consecutive first trimester miscarriages.

If a participant has experienced any of the following between or after a first trimester intrauterine miscarriages they are still eligible:

- Ectopic pregnancy
- Molar pregnancy
- 2nd trimester miscarriage

Please contact the CERM trial team cerm@warwick.ac.uk if you are unsure of a patient's eligibility. The CI or clinical delegate will review to confirm their suitability for participation in line with the protocol.

1.4 Chronic Endometritis Diagnosis

Chronic Endometritis will be diagnosed based on the density of CD138 staining cells within a tissue section of the biopsy. A positive screen will be defined as ≥ 5 CD138 positive cells per 10mm^2 .

1.5 Treatment

Women who screen positive for CE, are eligible and wish to participate will be randomised to either doxycycline 100 mg or matching-placebo twice a day for 14 days.

2. RATIONALE

2.1 Aims and hypothesis

The aim in this trial is to determine if doxycycline administered prior to conception improves pregnancy outcome in women with recurrent miscarriage associated with chronic endometritis and explore the mechanisms by which it could prevent miscarriage.

2.2 Justification

There is increasing evidence in the literature that CE is a treatable cause of RM. CE is persistent inflammation of the endometrium, detected by the presence of plasma cells in the endometrium and linked to miscarriage. The incidence and nature of endometrial dysbiosis associated with CE in RM has not been studied systematically; nor is it known if CE in RM is associated with sterile inflammation or chronic dysbiosis. It is not known if CE causes or compounds the endometrial defects associated with RM. It is also not known if resolution of CE, in response to doxycycline treatment, reverses endometrial defects.^{27 32 33} Observational studies suggest that antibiotic treatment may be effective in preventing miscarriage in women with CE, but this has not been tested in a randomised double-blind placebo controlled trial. Our observations suggest that CE may resolve spontaneously in some women but persists in others. Hence, there is a genuine need for placebo-controlled trial to determine the efficacy of doxycycline treatment on the subsequent on-going pregnancies in women with recurrent miscarriage associated with chronic endometritis.

2.3 Assessment and management of risk

A risk assessment has been completed by the Sponsor. The risk assessment will cover all risks associated with the trial and trial management. It will be updated on a continual basis as the risks change throughout the life of the trial.

2.3.1 Risk of Pregnancy

In the summary of product characteristics (SmPC) doxycycline is contra-indicated in pregnancy, because tetracycline use has been associated with problems with infant's teeth and bone development. However, a meta-analysis by Cross and colleagues (2016)³⁴ reported an absence of evidence of harmful effects when taken in pregnancy and there are no known reported cases or evidence of harm from taking doxycycline from day 1 to 14 of the menstrual cycle. Doxycycline is prescribed to pregnant women *"when travel to malarious areas is unavoidable during pregnancy, doxycycline can be used for malaria prophylaxis if other regimes are unsuitable, and if the entire course of doxycycline can be completed before 15 weeks' gestation"* (BNF, 2018-2019). This trial has been designed so there is minimal chance of fetal exposure in the following ways:

1. A pregnancy test is performed prior to taking doxycycline
2. Doxycycline/placebo is taken on the first day of the menstrual cycle so women are not pregnant when they start taking the intervention
3. The doxycycline/placebo are taken prior to ovulation, hence before pregnancy is possible –all women's cycles are reviewed
4. Women are advised and consent to use condoms
5. The half-life of doxycycline is 16-22 hours thus there will be minimal drug present one week after the drug is stopped should implantation occur.¹⁰

The doxycycline/placebo will start on the first day of their next menstrual cycle. We plan to start the intervention on day one of the cycle to ensure that the treatment is completed during the proliferative phase of the cycle, thus negating the risk of doxycycline exposure in early pregnancy.

If a participant reports she has a positive pregnancy test whilst taking the doxycycline/placebo she will discontinue taking the doxycycline/placebo. If the participant has a positive pregnancy test within 4 weeks of stopping the doxycycline/placebo she would have conceived in the cycle she took the medication. In both these cases she will be reassured that the risk to her infant is extremely small. These pregnancies, possibly exposed to peri-conceptual doxycycline will be followed up until birth when the baby will receive a full examination by a qualified healthcare professional within one week of delivery as per local practice. Any congenital abnormalities detected during pregnancy by ultrasound scan or by examination and imaging within a week of delivery should be recorded on the Serious Adverse Event Form and emailed to **cerm@warwick.ac.uk** within **24 hours** of the research staff becoming aware of the event. This will be monitored and reported as appropriate.

3. OBJECTIVES AND OUTCOME MEASURES

3.1 Primary objective

Does doxycycline given prior to conception improve the number of on-going pregnancies and total live births in women with recurrent miscarriage associated with chronic endometritis?

3.1.1 Primary outcome measure

Our primary outcome measure will be the total live births $\geq 24 + 0$ weeks, defined as total live births plus ongoing pregnancies $\geq 24 + 0$ weeks gestation at the end of the trial, in first or subsequent pregnancy.

The maximum denominator for this analysis will be 1,500 women randomised.

If a participant has a live birth $\geq 24 + 0$ weeks gestation in their first or subsequent pregnancy, their trial follow up is complete at the timepoint of delivery and no data on projected live births from subsequent pregnancies will be collected or analysed. Whilst some babies born at 22 and 23 of weeks of gestation survive, they are at risk of long-term disability and hence will not be included in this outcome measure.

3.2 Secondary objectives

1. To find out if doxycycline treatment improves CE.

2. To examine the separate effects of doxycycline on conception, early miscarriage, and late miscarriage. In addition, assess the mediation effect of each of these, on the primary outcome, with treatment as a covariate.

3.2.1 Secondary Outcome measures:

- On-going pregnancy at 12 weeks. Ongoing pregnancy is defined as the number of viable pregnancies, with a crown rump length >54 mm, reaching 12+6 weeks of gestation as a percentage of the total number of first pregnancies after the intervention
- Density and type of CD138+ cells in the endometrium before and after treatment
- Time to first conception
- Anticipated time to first live birth
- Live births, the proportion of women with a live birth on or equal to 24 weeks of gestation in their first pregnancy after randomisation.
- Pregnancy complications, in first pregnancy following randomisation lasting greater than 12 weeks; second trimester miscarriage, intrauterine death, preterm delivery, small for gestational age and placental abruption.
- Early pregnancy complications (e.g. ectopic pregnancy, molar pregnancy).
- Type of miscarriage, biochemical¹, gestational sac², fetal³, karyotype of miscarried tissue.

- A re-assessment of the ability of the CD138+ cell test to detect which patients could benefit from doxycycline will be undertaken. This analysis will use miscarriage, on-going pregnancy and live births per patient in women excluded from randomisation by having low CD138+ cell scores and those randomised to placebo.
- Termination for social reasons

¹ *Biochemical – Positive pregnancy test without ultrasound visualisation of pregnancy*

² *Gestational Sac – Presence of gestational sac on ultrasound without visualisation of fetus*

³ *Fetal – Presence of fetus on ultrasound with no fetal heart beating*

3.3 Exploratory Objectives

1. To find out if doxycycline treatment changes Lactobacillus-deplete microbiota to a Lactobacillus-dominated microbiota
2. To find out if doxycycline treatment, improves the differentiation potential and colony-forming activity of endometrial stromal cells
3. To find out if CE is related to heightened senescence of endometrial stromal cells

3.3.1 Exploratory Outcome measures

1. Evaluate change of Lactobacillus-deplete microbiota to a Lactobacillus-dominated microbiota after treatment.
2. Assess changes in differentiation potential and colony-forming activity of endometrial stromal cells after treatment.
3. Assess senescence associated β Galactosidase activity in patients with CE.

4. TRIAL DESIGN

This trial is a prospective, multi-centre, randomised, double blind adaptive designed trial, comparing a pre-conception course of doxycycline against placebo in up to 1500 women from sites in the United Kingdom. The trial is an adaptive design that allows frequent statistical review; leading to either continuation, stopping or adapting the trial to ensure maximal efficacy. Adaptive trial designs have the potential to markedly reduce the overall cost and duration of the trial by using interim statistical analysis, and modifying the design in the light of information already accumulated (e.g. stopping early or extending recruitment). Using ongoing pregnancy as a surrogate marker for live birth markedly reduces the overall cost and duration of the trial by reducing the time to knowledge of the outcome and builds in the necessary flexibility to enable an adaptive trial design. Our primary outcome measure will be total live births, both actual or anticipated first live births, at the end of trial data collection. This includes all completed, or ongoing at 24 + 0 weeks gestation, first or subsequent pregnancies after randomisation, as this is most meaningful to patients. The live birth outcome will include the effects doxycycline treatment may have on fertility, preterm birth, second trimester miscarriage and stillbirth.

We anticipate that around 3,062 women will have an endometrial biopsy, during the luteal phase of the women's menstrual cycle, to test for CE, defined as ≥ 5 CD138 positive cells per 10mm^2 . It is estimated that 50% will screen positive and be invited to participate in the randomised trial. Since stillbirths occur in roughly 1 in 250 births in England and Wales and 98% of all miscarriages occur prior to 12 weeks of pregnancy, ongoing pregnancy at $\geq 24 + 0$ weeks gestation is a very good marker of live births³⁵.

The trial comprises two stages:

- Patients will be registered into the screening trial and have an endometrial biopsy taken to test for the presence of CE (N=3,062)
- Women who screen positive for CE will be randomised into the randomised controlled trial of doxycycline versus placebo (N=1,500).

Within the main trial (CERM A) a subset of patients will be recruited to CERM B to determine if doxycycline treatment improves CE and microbiota compositions.

CERM B patients will all be recruited at University Hospital Coventry and Warwickshire NHS Trust. CERM B patients will follow the same pathway as CERM A patients but will have the following additional assessments:

- Patients will be registered into the screening trial, consented to the CERM B trial and have a vaginal, endometrial and cervical swab at registration.
- Women who screen positive for CE and are randomised into the trial will have a second endometrial biopsy following treatment.
- Women who screen positive for CE and are randomised into the trial will have a second vaginal, endometrial and cervical swab following treatment.

In order to analyse if doxycycline treatment improves CE and microbiota composition 200 paired endometrial biopsy and endometrial swab samples are required from patients before

and after treatment. Approximately 400 patients will be registered into CERM B and have the additional vaginal, endometrial and cervical swab at registration. Approximately 200 of these patients will screen positive for CE and be randomised into the trial. These patients will have the repeated endometrial biopsy and vaginal, endometrial and cervical swab following treatment. A random sample of vaginal and cervical swabs will be analysed to ensure no contamination of the endometrial swab sample.

5. TRIAL SETTING

Women will be recruited from NHS appropriate clinics such as Recurrent Miscarriage Clinics (RMC) and Early Pregnancy Units (EPU) or through Tommy's 'Recurrent Miscarriage' database in NHS organisations across the UK.

5.1 Site requirements:

- Sites must be able to take endometrial biopsy samples. Sites must adhere to the CERM A manual for collection of Endometrial Biopsies for the collection, shipment and tracking of endometrial biopsy samples.
- Sites must follow pharmacy procedures detailed in the trial treatments section of the protocol, including IMP labelling, storage, dispensing and accountability procedures.
- Sites must adhere to the data collection requirements given in the data management section of the protocol.
- Sites must comply with the CERM Trial monitoring procedures set out in the monitoring, audit & inspection section of the protocol.

All NHS organisations taking part in the trial will be responsible for registering and randomising patients into the CERM Trial.

University Hospitals Coventry & Warwickshire NHS Trust will also be responsible for recruiting CERM B patients.

5.2 Site Initiation

Before the trial can be initiated at site, the prerequisites for conducting the trial must be clarified and the organisational preparations made with the trial site. The trial manager will arrange a site initiation visit (SIV) which must be attended by key trial personnel at the site including the PI and pharmacy lead. This SIV involves a detailed presentation of the trial documents and discussion of unanswered questions. The PI is responsible for ensuring that all of the information presented at the SIV is passed on continuously to all those who are involved in the conduct of the trial.

Following site initiation, the research team will be in regular contact with sites by email, telephone and face-to-face, to support with the day-to-day management of the trial, and identify and discuss any problems with compliance to the protocol, recruitment pathway, barriers to recruitment, 'Site File' completeness.

5.3 Site staff Training

5.3.1 Principal Investigator (PI)

An appropriate, medically qualified, PI should be identified at each NHS organisation. The PI will have overall responsibility for the conduct of the trial at site. The PI will be responsible for:

- Ensuring that the trial is conducted as set out in the protocol and supporting document

- Delegating trial related responsibilities only to suitably trained and qualified personnel and ensuring that those with delegated responsibilities fully understand and agree to the duties being delegated to them
- Ensuring that CVs and evidence of appropriate training for all Site staff are available in the Investigator Site File
- Ensuring that all delegated duties are captured in the trial Delegation Log
- Ensure all AEs are recorded/documented appropriately and all SAEs are reported to the WCTU CERM trial team within 24 hours of their knowledge of the event.
- Accountability for trial treatments at their site.
- Ensuring the trial is conducted in accordance with ICH GCP principles
- Allowing access to source data for monitoring, audit and inspection
- Ensuring that all source data is complete and provided to the WCTU CERM trial team at regular intervals.

5.3.2 Research Team at site

All staff involved in trial specific duties will be required to have completed a Good Clinical Practice course and keep their knowledge up-to-date throughout the life-time of the trial.

5.3.3 Clinicians confirming eligibility and consenting to the trial

Clinicians confirming patient eligibility and consenting participants to the trial must be medically qualified.

5.3.4 Clinicians performing endometrial biopsies and vaginal, endometrial and cervical swabs

Clinicians taking biopsies and swabs will be competent to do so either by virtue of clinical role or appropriate specialist training on the technique for the trial (provided by CI or delegate). Trial specific guidance will be provided in the CERM A Manual for collection of Endometrial Biopsies and CERM B Manual for collection of Microbial Swabs. Clinicians taking biopsies and swabs are not required to have GCP training or be on the site delegation log if this procedure is routine in their clinical role.

6. ELIGIBILITY CRITERIA

As per GCP the decision as to whether a patient is eligible for entry into the trial (screening biopsy and RCT) is considered a medical decision and therefore this decision must be made by a medically qualified doctor. The initial eligibility assessment at the biopsy preparation stage, however, can be undertaken by other appropriate health care professionals such as research midwives.

Appropriately qualified staff assigned this responsibility must be named on the trial delegation log.

Confirmation of eligibility must be documented in the patients' medical notes.

WCTU CERM trial team will be available to answer any queries regarding eligibility criteria prior to registering a patient into the trial.

6.1 Inclusion criteria – biopsy preparation-pre-eligibility

The following eligibility criteria must be assessed and verbal consent obtained prior to sending patients a biopsy preparation kit. Biopsy preparation eligibility assessment can be performed a qualified healthcare professional this does not have to be a medically qualified doctor.

- Their age (≥ 18 to < 42)
- They have had 2 or more (consecutive first trimester) miscarriages
- They are not currently pregnant
- They have no known treatable cause of miscarriage (a treatable cause may be identified through further assessment)
- They have no uncontrolled diseases
- They are happy to use barrier contraception for 3 months
- They are not taking systemic antibiotics
- No known allergy or contraindication to doxycycline
- Their menstrual cycle is between 21 – 42 days
- Verbal consent to being sent a biopsy preparation kit

6.2 Inclusion criteria - screening biopsy

- Age ≥ 18 to < 42
- Two or more consecutive first trimester intrauterine miscarriages (≤ 14 weeks gestation).*
- Women who agree to use condoms as their method of contraception during the following cycles: biopsy preparation, screening-biopsy, waiting for the results and during the intervention.

*Participants cannot have had a live birth/still birth/termination in between or after their consecutive first trimester intrauterine miscarriages. Any non-visualised pregnancy loss

prior to 14 weeks gestation, including pregnancies of unknown location, will be considered an early miscarriage for the purpose of trial eligibility.

If a participant has experienced any of the following between or after an intrauterine first trimester miscarriages they are still eligible:

- Ectopic pregnancy
- Molar pregnancy
- 2nd trimester miscarriage

Please contact the CERM trial team cerm@warwick.ac.uk if you are unsure of a patients eligibility. The CI or clinical delegate will review to confirm their suitability for participation in line with the protocol.

6.3 Exclusion criteria – screening biopsy

- Known treatable cause(s) of RM for example*:
 - antiphospholipid antibody syndrome
 - thyroid disease
 - parental karyotypical abnormalities.
- Known sub-septate uterus.
- Poorly controlled diabetes (HbA1c ≥ 64 mmol/mol)
- Allergy to doxycycline or its excipients – refer to table 7 for full list
- Doxycycline contraindicated
- Systemic antibiotics in the current menstrual cycle
- Taking a medication that may interact with doxycycline – refer to table 9 for a full list.
- Myasthenia Gravis.
- Systemic lupus erythematosus (SLE).
- Immunodeficiency disorder.
- Known serious liver disease**¹
- Alcohol dependency**
- Long-term antibiotic(s) use.
- Menstrual cycle <21 or >42 days.
- Any co-morbid disease or condition that would make the patient unsuitable for the trial**¹
- Unable to give informed consent.
- Patient has received treatment with an investigational medicinal product (IMP) on another clinical trial in the last 90 days.
- Women who are breast feeding.
- Pregnancy

* Participant may not have undergone tests for treatable cause of RM prior to registration. If treatable cause for RM identified after registration the participant cannot be randomised.

** As judged by a medically qualified doctor assessing trial eligibility informed by referral letter from GP and hospital records

¹ If a clinician has doubts about a participants' suitability for the trial because of a long-term medical condition they should undertake a Full Blood Count (FBC) and Liver function tests (LFTs); in order for a woman to be randomised into the trial the following should apply:

- WBC $>3 \times 10^9/L$,
- Neutrophils $>1.5 \times 10^9/L$,
- Platelets $>75 \times 10^9/L$, Hb $>100g/L$
- Bilirubin $<1.5 \times ULN^*$
- AST/ALT $<3 \times ULN^*$
- Albumin $>30g/dL$.

* ULN = Upper Limit of Normal

All required additional checks must be documented in the patients' medical notes

Table 7 - excipients of doxycycline/placebo capsules

Excipient
Doxycycline hyclate
Gelatin
Lactose/1% Magnesium Stearate Blend
Titanium Dioxide (E171)
Red Iron Oxide (E172)
Shellac Glaze
Sodium lauryl sulfate
Starch
Quinoline Yellow (E104)
Erythrosine (E127)
Patent Blue V (E131)
Iron oxide black (E172)
Propylene glycol

6.4 Inclusion criteria - RCT

- Women with ≥ 5 CD138+ cells/ $10mm^2$.

6.5 Exclusion criteria – RCT

- Treatable cause(s) of RM (as defined in section 6.2)*
- A course of systemic antibiotics between screening registration and randomisation to RCT***
- A delay of longer than three months between biopsy result and randomisation to RCT***
- Known serious liver disease**1
- Taking a medication that may interact with doxycycline – refer to table 9 for a list of known interactions.
- Any co-morbid disease or condition that would make the patient unsuitable for the trial**1
- Pregnancy

- Any change to eligibility criteria at screening that would deem the patient ineligible for the trial


*, ***, ¹: see section 6.3***If a woman has a course of systemic antibiotics between screening registration and randomisation or was registered for screening over three months before randomisation to the RCT they will not be eligible for trial randomisation at the time. These women should be given the option to re-screen and have another biopsy to confirm eligibility for randomisation.

6.5 CERM B Exclusion (repeat endometrial biopsy and vaginal, cervical and endometrial swabs)

- Pregnancy

7. TRIAL PROCEDURE

Figure 2 – Pathways to recruitment



* The end of overall trial follow-up may truncate an individual participant's follow-up to a maximum of month 12.

7.1 Patient Identification

Women will be identified to participate in the following two ways:

7.1.1 Women on the Tommy's 'Recurrent Miscarriage' database

Women on the Tommy's 'Recurrent Miscarriage' database have had investigations for a treatable cause of their miscarriage and have given consent to be contacted for research purposes. These women will be sent an introduction letter and/or given a participant information sheet explaining about the trial and what participation would involve, either by post or email depending on their stated preference. After one week women will be contacted, by telephone, by a member of the hospital research team to discuss the trial, answer any questions and discuss participation. If women would like to participate, their initial eligibility will be checked by a member of the hospital research team and verbal consent will be taken and documented in their medical notes. Confirmation of verbal consent should also be recorded on the CERM trial screening log.

7.1.2 Women referred to a recurrent miscarriage clinic or early pregnancy unit (EPU)

Women with a clinician referral to a recurrent miscarriage clinic, EPU or other appropriate clinic (site dependant) from a gynaecologist, obstetrician, or General Practitioner (GP) who have not had investigations into the cause of their RM will be sent an appointment to attend for investigations as per standard practice by the direct care team.

Separately a member of the direct clinical care team* will send and/or give women an invitation letter and a participant information sheet explaining about the trial and what participation would involve and inviting women to contact a member of the hospital research team if they would like more information or to participate in the trial. If women would like to participate, their initial eligibility will be checked by a member of the hospital research team and verbal consent will be taken and documented in their medical notes. Confirmation of verbal consent should also be recorded on the CERM trial screening log.

Invitation letters and participant information sheets can also be sent/given to women with a clinician referral to a recurrent miscarriage clinic or EPU if they have already undergone investigations into the cause of their RM but a treatable cause has not been identified.

If investigations reveal a treatable cause of their recurrent miscarriage they will receive treatment and will not be eligible for the trial. If a treatable cause of their recurrent miscarriages is not identified they will be eligible for the trial.

If women on either pathway would prefer to talk about the trial and what participation would mean for them this can be arranged remotely via telephone/video-call or face-to-face, depending on local practice.

Women who self-refer will be advised to contact their GP to discuss referral to one of the recurrent miscarriage clinics or EPUs taking part in the trial.

*If the PI states that research team members contribute significantly to clinical care then some individuals can be both members of the research and clinical care teams.

7.1.3 Participant Identification Centres (PICs)

PICs will be used to identify potential research participants. PICs can do this by identifying participants by processing their personal data (e.g. through carrying out a search of patient records to identify individuals that potentially meet the trials eligibility criteria).

The potential participants identified at PICs are also eligible for self-referral into the trial via their GP.

PICs can send and/or give potential participants a PIC invitation letter with a patient information sheet enclosed. This information given to the potential participant explains who to contact at a research site if they wish to have their eligibility explored further for the trial.

7.1.4 Screening Log

A Screening Log must be maintained by each site to document all patients that have contact with the research team about the trial. Where possible, the reason for non-entry to the trial must be documented. This must be emailed to WCTU CERM trial team cerm@warwick.ac.uk on a regular basis when requested. Patient names, hospital numbers or other identifiers must not be recorded on the Screening Log.

7.2 Biopsy Preparation

It is important to women, who are trying to conceive, to minimise the time they are using contraception, therefore to reduce this time we are asking women to prepare for their biopsy before they attend clinic. If women would like to participate, their initial eligibility will be checked by a member of the hospital research team and verbal consent will be taken and documented in their medical notes. Confirmation of verbal consent should also be recorded on the CERM trial screening log. A biopsy preparation kit which includes a period tracker, condoms and a ovulation testing kit will be posted out or given to women if they meet face-to-face with a member of the hospital research team. Instructions on using the kit will be included. Women will contact the clinic when they are ovulating, to arrange to come into clinic for a biopsy 10 (\pm 4) days later, or if the test does not indicate ovulation, to arrange to come into clinic for a biopsy on day 23 (\pm 3 days) of their cycle.

7.3 Screening

To enter the trial women will be asked to consent to use barrier contraception for either two or three menstrual cycles depending on whether they screen positive for CE (Table 8). However, this may be longer if a woman does not use barrier contraception, has a condom failure during one of the cycles or personal circumstances intervene.

Table 8 – trial cycles

Cycle	Procedure
1	Biopsy preparation cycle
2	Screening cycle: endometrial biopsy, microbial swab of the vagina*, endometrium* and cervix*
3	Results cycle
4	Treatment cycle: RCT for screen positive women

***CERM B only**

The endometrial biopsy will be taken in the luteal phase of the cycle at around 10 (\pm 4) days after ovulation. Instructions in the 'biopsy preparation kit' will request women to record their menstrual cycle, starting from the first day of bleeding in their next period, using the period tracker provided. Condoms are provided and more can be obtained by contacting the hospital research team, family planning services and some GP surgeries.

7.3.1 Consent for Screening and RCT

When the woman comes to clinic for their biopsy they will meet with a member of the hospital research team who will explain the process and answer any questions. Women will be informed that they are welcome to bring a partner, family member or friend to this meeting, if local visitation practices allow. Eligibility for the screening phase will be checked by a medically qualified doctor. A pregnancy test will be undertaken, if the test indicates the woman is pregnant, the biopsy will not be taken and she will be referred to her GP who will arrange her care.

Women will confirm participation in the trial by signing a consent form. It should be made clear that only women who screen positive for CE will be able to participate in the randomised controlled part of the trial. The consent process will be documented in the participant's medical notes.

Following consent the site research team should ensure that patients have been given a copy of the signed informed consent form and PIS. A pregnancy testing kit will also be provided in order to confirm eligibility prior to the randomisation of women who screen positive for CE and wish to progress to the RCT.

7.3.2 Consent CERM B

Women attending UHCW RM clinic will be asked to consent to CERM B. Women in CERM B will consent to having a microbial swab of the vagina, endometrium and cervix taken in addition to the endometrial biopsy. These women will be given the option of consenting to CERM A if they do not wish to have the microbial swabs.

Following consent the site research team should ensure that patients have been given a copy of the signed CERM B informed consent form and CERM B PIS.

7.4 Registration – screening

The site should log on to the CERM registration/randomisation portal to register the participant and obtain a trial ID number to identify the participant for the purposes of the trial. Sites should access the portal via the link below:

<http://ctu.warwick.ac.uk/CERM>

Site staff authorised to register and randomise participants to the CERM trial will be provided with a username and password to access the registration and randomisation system as part of the site set up process.

In the unlikely event the registration/randomisation portal is not available staff will contact the WCTU CERM Trial Team (contact details given in Table 4) who will be available week days between 09:00 and 17:00 (16:00 on Fridays) excluding bank holidays & Christmas closure.

An email will be sent to the PI and lead contact at site confirming patient registration details and trial ID number.

Following registration the site research team should ensure that they update the screening log and ensure the participants details are entered on to the local sites participant enrolment log.

Refer to the tissue sample section of the protocol for details on the collection and shipment of the endometrial biopsy and microbial swab of the vagina, endometrium and cervix.

7.5 Biopsy results

Results of the biopsy will be received up to four weeks after receipt of biopsy by the central laboratory (UHCW).

Once results have been received the investigator will complete and send the participant's General Practitioner (GP) a letter and copy of the Participant Information Sheet to inform them of their patient's participation in the trial. The CERM B PIS will be sent as appropriate.

7.6 Randomisation

It is expected that around half the women will screen positive for CE. If the results indicate that a woman has CE she will be invited to proceed to participate in the randomised controlled part of the trial to receive either a course of doxycycline an antibiotic (the intervention group) or placebo (the control group).

7.6.1 Verbal Reaffirmation of RCT Consent

Women who screen positive for CE will be contacted to inform them of their results and to discuss their continued progression to participation in the RCT. An appointment will be made to meet with a member of the hospital research team remotely or face to face, who will revisit the RCT and what their continued participation would involve including the potential risks and benefits of participating. Women will be referred to the trial PIS. An additional PIS can be posted or emailed to them if required. All women will have as much time as they need to confirm they are happy to continue with the trial, have the opportunity to discuss participation, ask questions and consult with health care professionals, family and friends.

RCT eligibility will be checked and the women will verbally reaffirm consent to participation in the RCT. Final eligibility for the RCT must be assessed and verbal consent must be taken by a medically qualified doctor. The eligibility and the patients verbal reaffirmation will be documented in the participants medical notes.

A home pregnancy test will be undertaken to confirm eligibility prior to randomisation. Women will be asked to use the pregnancy testing kit that will have been provided during the screening and biopsy visit and asked to provide verbal confirmation of the pregnancy test result. Alternatively, a pregnancy test may be performed on site if the woman attends

for a face to face appointment with the hospital research team. If the test indicates the woman is pregnant, she will be referred to her GP who will arrange her care. If the pregnancy tests indicates the woman is not pregnant she will be randomised to receive doxycycline/placebo. Where women expect to delay their commencement of doxycycline/placebo, sites are encouraged to consider delaying randomisation so that the intervention commences in the subsequent menstrual cycle. Randomisation can be delayed up to three months following biopsy result.

Participants who screen positive for CE and are either ineligible for randomisation or do not wish to continue to randomisation will not be followed up.

7.6.2 Verbal Reaffirmation of RCT CERM B Consent

Women attending the UHCW site will be asked to verbally reaffirm consent to the CERM B RCT. These participants will verbally reaffirm to having a second endometrial biopsy and vaginal, endometrial and cervical swabs being taken.

Screen-positive women in CERM B will have a biopsy during the luteal phase (10 ± 4 days) after ovulation during the intervention cycle. CERM B participants should be provided with a second biopsy preparation kit. The preparation, procedure and analysis will be identical to the first biopsy procedure (see the tissue samples section of the protocol for further details). Women who are randomised to CERM B are free to decline the second endometrial biopsy and vaginal, endometrial and cervical swabs if they later wish.

7.7 Randomisation – Randomised Controlled Trial

The trial ID number allocated during registration will be used as part of the randomisation process.

Sites should log on to the CERM registration/randomisation portal to randomise the participant and obtain a drug pack number. Sites should access the portal via the link below:

<https://ctu.warwick.ac.uk/CERM>

In the unlikely event the registration/randomisation portal is not available please contact the WCTU CERM Trial Team (contact details given in table 4) who will be available week days between 09:00 and 17:00 (16:00 on Fridays) excluding bank holidays & Christmas closure.

Women will be randomised using minimisation, balancing by age, number of previous miscarriages and site.

An email will be sent to the PI and lead contact at site confirming participant randomisation details, trial ID number and participant drug pack number.

Following randomisation the site research team should ensure that the participant's details are updated onto the local site's participant enrolment Log.

Once a participant is randomised they will attend the site within 7 days of their confirmed negative pregnancy test* in order to be provided with the doxycycline/placebo by the hospital research team. They will also be provided with the 'Taking my capsules on the CERM trial: Chronic Endometritis and Recurrent Miscarriage' leaflet and instructed as follows:

- Take one capsule, twice a day, 12 hours apart for 14 days starting on day one of their menstrual cycle.
- Record when they take their capsules on the treatment diary provided.
- Use condoms and to not have unprotected sexual intercourse during their entire menstrual cycle and not just whilst taking the doxycycline/placebo. This is the last cycle women will be asked to use condoms and to not have unprotected sexual intercourse.
- Given a CERM Trial participant card. A member of the hospital research team should write the drug pack number allocated onto this card. This should be carried with the participant at all times whilst taking the capsules. If a replacement is needed they should contact their local site research team.
- Participants will be reminded to undergo a urine pregnancy test as soon as their menstrual periods are delayed or a pregnancy is suspected and to contact the site research team immediately.

*If the collection of IMP is delayed beyond 7 days women will be asked to repeat the pregnancy test on the day of collection. Women are reminded during the randomisation call that they should continue to use barrier contraception during the results and treatment cycles and should contact the site team immediately if pregnancy is suspected.

7.8 Blinding

The trial is double blind, neither the participants, clinicians, pharmacist or the research team know the treatment allocation. All drug packs containing either doxycycline or placebo have an individual pack number but are otherwise identical. Unblinding is possible if clinically necessary (figure 3). Routine unblinding following request from a participant will be possible after completion of the trial.

7.8.1 Emergency unblinding

Most clinical scenarios, including suspected allergic reaction, are managed by stopping the doxycycline/placebo capsules. A request on the grounds of safety can be made by any clinician involved in the medical care of the women. The CI or delegate will unblind using the interactive voice response system linked to the Warwick CTU database. Only authorised personnel will be able to access this system using a unique user specific passcode. A paper backup system with sealed code break envelopes is accessible in the event of failure of the Warwick CTU database. Only authorised personnel will be able to access this paper system.

The unblinding will be documented on the trial database, an unblinding form will be completed with the justification and reported to the statistician, TMG (including sponsor), TSC and DMC. If an emergency unbinding request is not actioned, an unblinding form will be completed with the justification and reported to the statistician, TMG (including sponsor), TSC and DMC.




Figure 3 – Emergency Unblinding procedure

7.9 Follow up for women who screen negative for CE

If the results indicate that a woman does not have CE she will not be eligible to participate in the RCT. Women will be contacted to inform them of the results. Women will then be followed-up at 3, 6 and 12 months to collect details of any confirmed first pregnancies conceived within 12 months from receiving the result of the endometrial biopsy until eight weeks post-delivery or miscarriage. If a screen negative participant confirms pregnancy during the follow-up period, they should be contacted at the assessment time points outlined in Sections 9.6 – 9.9 and information should be collected and recorded as specified.

7.10 Patient information and consent review and guidance

It is important for this trial that we include women who are not fluent in written and/or spoken English. Translators should be provided during recruitment to allow those who are not sufficiently fluent in spoken English to be adequately informed about the trial.

7.10.1 Consent overview




Figure 4 – CERM consent overview

*CERM B is for UHCW patients only

7.11 End of trial

The trial is an adaptive design that allows frequent statistical review; leading to either continuation, stopping or adapting the trial to ensure maximal efficacy. The trial will finish recruitment once 1500 women have been randomised, or before this dependent upon efficacy, futility or decision by the trial funder. Any women who have already been

registered into the trial prior to 1500 women being randomised, who receive a positive CE diagnosis after this date, will also be randomised. Follow-up information will be collected for 12 months after the last participant is randomised.

The trial will end when the database is locked following data entry from the last follow-up. The trial will be stopped prematurely if:

1. Mandated by the Ethics Committee.
2. The TSC, based on the recommendations from the DMC, decide the trial should end.
3. If recruitment falls substantially below target after recruiting for six months i.e. ≤ 68 women randomised.
4. EME funding ceases.

The HRA Research Ethics Committee and MHRA will be notified in writing within 15 days if the trial has been concluded or terminated early.

8. TRIAL TREATMENTS

Intervention Arm: Doxycycline 100mg orally twice daily for 14 days.

Control Arm: Matching-placebo orally twice daily for 14 days.

8.1 Name and description of investigational medicinal product(s)

The investigational medicinal products (IMPs) are:

- Doxycycline 100mg capsules
- Matching placebo capsules

Both IMPs will be over-encapsulated and packaged to look identical in appearance, colour, shape and weight.

8.2 Regulatory status of the drug

IMP will be sourced, over-encapsulated and repackaged by Sharp Clinical Services Ltd under their MIA(IMP). Batch documentation will be held by Sharp Clinical Services and Qualified Person (QP). Batch Release Certificates will be sent directly to the sponsor and kept centrally.

Sharp Clinical Services will source Doxycycline from a product with a UK/EU marketing authorisation. The matching-placebo will be made by Sharp Clinical Services.

8.3 Product Characteristics

IMPs will have a simplified IMP dossier prepared by Sharp Clinical Services and a copy will be kept centrally by the sponsor.

The summary of product characteristics (SmPC) for doxycycline will be used as reference safety information (RSI) for the trial. This will be maintained in the TMF and will be updated periodically. Any use of an updated SmPC will be managed by WCTU with approval from the sponsor and authorisation from the MHRA will be obtained prior to use and dissemination to sites.

8.4 Drug storage and supply

IMPs will be supplied by Sharp Clinical Services who will over-encapsulate commercially available doxycycline and manufacture a matching placebo capsule. The manufacture will be done under an MIA(IMP) license following Good Manufacturing Practice (GMP) & Medicines for Human Use (Clinical Trials) Regulations 2004 as amended.

Sharp Clinical Services will assign a qualified person (QP) to be responsible for batch release and provide support for product complaints/queries for the duration of the trial. Details of specific arrangements will be documented in a GMP Technical Agreement with the Sponsor.

IMP will be supplied as blinded packs of doxycycline 100mg/placebo capsules, each containing a 14 day supply. Each pack will have a unique pack number.

8.4.1 Temperature monitoring and excursions

IMP must be stored at ambient temperature 15-25 degrees Celsius. Sites will be required to monitor the temperature using at least a min/max thermometer on a daily basis. Temperature logs should be kept either centrally on site or within the pharmacy site file. Where temperature logs are kept centrally a copy of the temperature log should be added to the pharmacy site file at the close of the trial.

A temperature excursion is defined as any temperature outside of 15-25°C. In the event of a temperature excursion either during storage or during delivery the site will need to quarantine affected stock and notify WCTU CERM trial team who will contact the Sponsor to make a decision about the usability of the stock based on any extended stability data or accelerated stability testing from the manufacturer or other published data.

8.4.2 Ordering

The WCTU CERM drug management system will be used for ordering, receipt and randomisation of IMP packs.

WCTU will order the initial supply of doxycycline/placebo for each site and will monitor stock levels at each site using the CERM drug management system. WCTU will set a minimum stock level for sites depending on recruitment, when stock levels reach this threshold WCTU will re-order supplies of doxycycline/placebo for site as required. If sites require additional stock or need to adjust their stock holding they should contact WCTU CERM trial team by email. The turnaround time for delivery of the IMP will be five working days.

8.4.3 Shipment

IMP will be delivered to sites by courier from Sharp Clinical Services using temperature controlled vehicles in preference (e.g. Polar Speed); should this not be possible insulated shippers (e.g. AmbiTech) will be used. Each shipment will contain a single use electronic temperature monitoring device (e.g. USB TempTale 4). QP batch release certificates will not be sent to sites and will be held centrally by the sponsor. If sites require QP batch release certificates they should contact the WCTU CERM trial team.

8.4.4 Receipt

On receipt of IMP, sites will ensure that supplies are in good condition. Sites will need to acknowledge receipt of IMP to WCTU by email to cerm@warwick.ac.uk. WCTU will then update details on the drug management system. Sites will download the data from the enclosed temperature monitoring device using the instructions included with the shipment and print off the PDF data.

The temperature monitoring data file and shipment paperwork will be kept in the pharmacy site file.

If stock is not in good condition sites will notify WCTU immediately and quarantine the stock. The sponsor will make a decision as to the suitability of stock and whether stock needs to be destroyed on site or returned to Sharp Clinical Services.

IMP should be kept segregated from general hospital supplies, in a secure location with restricted access.

8.4.5 Distribution

IMP must not be distributed to other sites without prior discussion with the sponsor.

8.4.6 Return

In the event IMP needs to be returned, WCTU will make arrangements with the site for a courier to collect.

8.4.7 Product recall

WCTU will notify sites in the event of a product recall. Any affected stock will be quarantined on site until a decision can be made about the usability of the stock.

8.4.8 Destruction

IMP must not be destroyed on site without prior approval from the sponsor or delegated representative. Sites will need to keep a record of destruction/disposal of IMP. Evidence of destruction or disposal will need to be sent to WCTU.

8.5 Preparation and labelling of Investigational Medicinal Product

The IMP will be labelled to ensure, protection of the participant, traceability, identification of the trial, identification of the product and to facilitate proper use of the IMP in accordance with Volume 4 of Good Manufacturing Practices, Annex 13 (Manufacture of investigational medicinal products).

Sample labels will be created by the Sponsor and will be provided to the MHRA for approval prior to manufacture.

Sites may add additional dispensing labels to the product as part of standard hospital dispensing practice. Any additional labelling should not contradict or obscure the product label. Any local labelling will be sent to WCTU for prior approval.

8.5.1 Prescribing and Dispensing

Following randomisation of a participant into the trial, WCTU will assign the participant drug pack number. The drug pack number assignment will be blinded and sent to the investigator and pharmacy by email.

The Principal Investigator on site or a medical doctor delegated by them will prescribe trial medication.

The prescription can be created as per local practice, but must have documented as a minimum the trial name, trial ID number, and pack number assignment. A copy of the prescription template must be forwarded to WCTU for review prior to site activation.

Dispensing will be done by the site hospital pharmacy. Packs will be dispensed according to the drug pack number assigned to the participant.

8.5.2 Accountability, Reconciliation and Destruction

The dispensing of the trial medication will be recorded in pharmacy on the Pharmacy IMP Accountability Log.

The accountability log should allow for full traceability. Accountability logs will record as a minimum the manufacturer, batch number, expiry dates and the participant's trial ID number, in order to maintain traceability of the stock issued and returned within the trial.

At the end of the trial any unused IMP will be quarantined pending Sponsor approval for destruction. Destruction of IMP should follow local waste disposal practice. All destruction of IMP must be recorded on the Pharmacy IMP Accountability Log.

Sites may use their own accountability logs provided they contain the minimum requirement from the sponsor and WCTU approval has been received prior to use.

8.6 Dosage schedules

8.6.1 Dose

All participants should take Doxycycline 100mg/placebo twice a day orally for 14 days starting on day one of participants' menstrual cycle.

8.6.2 Administration

The capsules should be swallowed whole with plenty of fluid in either the resting or standing position and well before going to bed for the night to reduce the likelihood of oesophageal irritation and ulceration.

If gastric irritation occurs, it is recommended that doxycycline/placebo capsules be given with food or milk. Absorption of doxycycline is not notably influenced by simultaneous ingestion of food or milk.

Please ensure participants are counselled according to the Taking my capsules on the CERM Trial: Chronic Endometritis and Recurrent Miscarriage participant information leaflet.

8.6.3 Missed doses

If a dose of doxycycline/placebo capsules is missed, the dose should not be doubled to make up for the missed dose, instead the missed dose should be taken within a window of 6 hours and then the next dose should be taken at the right time. A dose is considered missed if it has been more than 6 hours since it's scheduled time.

If vomiting occurs shortly after taking the dose then another dose can be taken within 2 hours of vomiting, otherwise take the next dose at the right time.

8.6.4 Precautions in renal failure

Participants can be dosed as normal in the event of acute renal failure.

There is no significant difference in the serum half-life of doxycycline in individuals with normal and severely impaired renal function.

Excretion of doxycycline by the kidney is about 40% every 72 hours in individuals with normal renal function. This percentage excretion may fall to a range as low as 1-5% every 72 hours in individuals with severe renal insufficiency (creatinine clearance below 10ml/min).

8.6.5 Precautions in hepatic failure

Participants who develop signs of hepatic failure during treatment should have IMP discontinued and be treated with standard medical care.

A clinical assessment will be made at the start of the trial and if the investigator feels there is a clinical need to have additional blood test monitoring then this can be done at the discretion of the clinician.

Women will be excluded if they have any symptoms or history of liver failure – if clinically indicated then a blood test can be done.

If applicable, CTCAE grade 1 toxicity (Bilirubin $<1.5 \times \text{ULN}$, AST/ALT $<3 \times \text{ULN}$, Albumin $>30 \text{g/dL}$) will be acceptable for entry and ongoing participation into the trial.

8.6.6 Precautions in haematological toxicity

A clinical assessment will be made at the start of the trial and if the investigator feels there is a clinical need to have additional blood test monitoring then this can be done at the discretion of the clinician.

If applicable, full blood count (FBC) CTCAE grade 1 toxicity (WBC $>3 \times 10^9/\text{L}$, Neutrophils $>1.5 \times 10^9/\text{L}$, Platelets $>75 \times 10^9/\text{L}$, Hb $>100 \text{g/L}$) will be acceptable for entry and ongoing participation into the trial.

Participants should be monitored for signs and symptoms of anaemia and thrombocytopenia.

8.7 Dosage modifications

Dose reductions and dose delays are not permitted in the trial. Treatment will be discontinued for the following reasons:

- Hypersensitivity reaction to doxycycline/placebo or excipients.
- Infection.
- Pregnancy or breast feeding.
- Visual disturbances (including loss of vision) or benign intracranial hypertension.
- Haematological toxicity greater than CTCAE grade 1.
- Hepatic toxicity greater than CTCAE grade 1.
- Rashes including maculopapular and erythematous rashes.
- Non-compliance with medication.

8.8 Known drug reactions and interaction with other therapies

Table 9 - medications known to interact with doxycycline and prohibited from being taken during the intervention

Medication name
Warfarin
Penicillin
Antacids containing aluminium, calcium, magnesium or other drugs containing these cations; oral zinc, iron salts or bismuth preparations
Barbiturates, carbamazepine, primidone, phenytoin
Methoxyflurane(used as inhalation anaesthesia in emergency departments or prior to surgery)
Ciclosporin
Rifampicin
Ergotamine
Methysergide
Methotrexate
Kaolin
Sucralfate
Quinapril
Retinoids (vitamin A or retinoids. Retinol, retinal, tretinoin (retinoic acid), isotretinoin, alitretinoin, etretinate, acitretin, adapalene, bexarotene, and tazarotene)
Oral typhoid vaccines
Fluorescence test
Drugs with the potential to cause hepatotoxicity should be avoided.
Avoid retinoids and vitamin A. Caution in use of creams that contain vitamin A or retinoids: retinol, retinal, tretinoin (retinoic acid), isotretinoin, alitretinoin, etretinate, acitretin, adapalene, bexarotene, and tazarotene.

8.9 Concomitant medication

Avoid alcohol and drugs with the potential to cause hepatotoxicity.

If a participant is randomised and then required to take any other antibiotics concomitantly with doxycycline/placebo, this can continue at the discretion of the participant's GP or treating clinician. The trial eCRF will record this information.

8.10 Trial restrictions

There are no specific dietary restrictions.

Participants must not use oral contraception and instead use condoms or refrain from unprotected intercourse from the menstrual cycle prior to screening and for the duration of treatment.

8.11 Assessment of compliance with treatment

Participants will be asked to return any medication at the end of treatment. Any medication returned will be sent to pharmacy and recorded on the accountability log.

Participants will be required to keep a treatment diary of doses taken and document any missed doses. Treatment compliance will be reviewed following treatment completion (in-person or via telephone). Patients will be asked to refer to their treatment diary during this compliance review. At the end of the patient's participation in the trial any unused IMP will be returned to pharmacy to be counted and destroyed.

Where site Pharmacies are not accepting medication returns women will be asked to retain any unused medication safely at home until such point that this can be returned.

9. TRIAL ASSESSMENTS

Please refer to the Table 5 CERM Schedule of Events which outlines the assessments at each trial Visit.

Details of all trial assessments should be written in the participants medical notes.

9.1 Screening and Registration

The following assessments should be completed during the screening and registration phase of the trial to evaluate patient eligibility. Written informed consent must be obtained prior to any trial specific assessments or investigations taking place.

- Demographics
- BMI (Height & Weight)
- Smoking history
- Medical History
- Obstetric History
- Pregnancy History
- Concomitant medication review
- Pregnancy Test
- Contraception review
- Period review

9.2 Screening

Following registration all participants will have the following assessments:

- Endometrial Biopsy

The endometrial biopsy should be handled as specified in the tissue sample section of the protocol.

9.2.1 CERM B (UHCW only n~400 participants)

- Vaginal Swab
- Endometrial Swab
- Cervical Swab

This should be taken at the same time as the Endometrial Biopsy.

9.3 Randomised Controlled Trial

The following assessments should be completed during the randomisation phase of the trial to evaluate patient eligibility. Verbal re-affirmation of consent must be obtained for the randomised controlled trial prior to any RCT trial specific assessments or investigations taking place.

- Confirmation of CE
- Concomitant medication review
- Pregnancy Test
- Contraception review
- Period review
- Adverse Events

CERM B participants should be provided with a second biopsy preparation kit. CERM B participants with a positive CE result should be reminded to contact the clinic when they are ovulating, to arrange to come into clinic for a biopsy 10 (\pm 4) days later, or if the test does not indicate ovulation, to arrange to come into clinic for a second biopsy on day 23 (\pm 3 days).

9.4 Treatment completion

The following assessments should be completed (via telephone) after the participant has completed their course of capsules and captured on the Treatment Completion Form:

- Check if the participant has missed any doses
- Check if participant completed the full course of treatment
- Adverse Events
- Concomitant medication review
- Contraception review

Participants will be asked to refer to their treatment completion diary and reminded to return any unused medication back to pharmacy.

9.4.1 CERM B participant post treatment completion – UHCW ONLY

In addition to the assessments listed in section 9.4 CERM B participants (n~200) will undergo the following assessments 10 (\pm 4) days after ovulation following treatment completion or on day 23 (\pm 3 days) of their cycle:

- Pregnancy test
- Period review
- Endometrial Biopsy
- Vaginal Swab
- Endometrial Swab
- Cervical Swab

The UHCW research team will keep in regular contact with these participants.

Participants should be asked to bring in their treatment diary and any unused medication. Treatment completion assessments listed in 9.4 will be completed at this visit.

9.5 Pregnancy review

Participants should be reminded to undergo a urine pregnancy test as soon as their menstrual periods are delayed or a pregnancy is suspected and to contact the site research team immediately.

Communication with participants will then be via telephone until a urine pregnancy test is positive (as per local policy). At each contact a member of the hospital research team will check if participants are trying to conceive, their pregnancy status and pregnancy outcome.

9.5.1 Women who do not have CE and are not randomised

Research staff at site will try to contact participants at 3, 6 and 12 months via telephone, from receiving the result of the endometrial biopsy until first pregnancy outcome or demise or until 12 months post biopsy result if the participant does not report a pregnancy in this time.

Details of any confirmed first pregnancies should be recorded. If a screen negative participant confirms pregnancy they should be contacted at the assessment time points outlined in Sections 9.6 – 9.9 and information should be collected and recorded as specified.

9.5.2 Women with CE who are randomised.

Research staff at site will try to contact randomised participants at 3, 6, 12 and 24 months via telephone, from 14 days post-first trial treatment (14 days after first capsule taken). Research staff should schedule in these calls with participants at each contact. The end of overall trial follow-up may truncate an individual participant's follow-up to a maximum of month 12.

If a randomised participant confirms pregnancy they should be contacted at the following assessment time points (Sections 9.6 – 9.9) and information should be collected and recorded as specified. If a pregnancy outcome $\geq 24 + 0$ weeks gestation is recorded, the participant will be followed up at 8 weeks post pregnancy and their trial follow-up will cease. If a pregnancy outcome < 24 weeks gestation is recorded, the participant will return to the aforementioned 3, 6, 12 and 24 month follow-up schedule.

If a randomised participant has not conceived during the trial by the 24 month follow-up, their trial follow-up will cease. Participants who have conceived by the 24 month follow-up but who are not currently pregnant at month 24 will be contacted at the end of the trial for

a final follow-up. Participants who are currently pregnant at month 24 will be followed up as per Sections 9.6 – 9.9.

9.6 12 week assessment– standard practice 12 week ultrasound scan (+/- 2weeks)*

- Pregnancy Confirmation (if not previously collected)
- Ultrasound (standard practice booking scan)
- Crown rump length
- Gestational Age
- Viable pregnancy assessment
- Congenital abnormality
- Concomitant medication review
- Pregnancy complications (if appropriate)
- Collect unused medication (if applicable/not previously collected)

9.7 20 – 24 week assessment – standard practice 20-24 week ultrasound scan (+/- 2 weeks)*

- Ultrasound
- Crown Rump Length
- Viable pregnancy assessment
- Gestational age
- Concomitant medication review
- Pregnancy complications (if appropriate)
- Congenital abnormality

9.8 Additional visits/ultrasound scans as per standard practice*

If participant has an additional visit/ultrasound scan between 12 weeks - 24 week please record the following:

- Crown rump length (if recorded)
- Gestational Age
- Viable pregnancy assessment

9.9 End of pregnancy assessment or follow-up(6 – 8 weeks post end of pregnancy)

9.9.1 Gestation $\geq 24 + 0$ weeks*

- Pregnancy outcome assessments
- Concomitant medication review

- Placental Histology
- Congenital abnormalities
- Pregnancy complications (if appropriate)
- Postpartum Maternal and infant infections
- Maternal infections 8 weeks post delivery

This will be the final follow up for the participant if their pregnancy gestation was \geq than 24 + 0 weeks.

9.9.2 Gestation <24 weeks – THIS CAN BE COMPLETED FROM HOSPITAL RECORDS AND DOES NOT HAVE TO BE PARTICIPANT REPORTED

- Pregnancy outcome
- Products of conception cytogenetics

For pregnancies that end < 24 weeks gestation, randomised participants should revert back to telephone follow-up as stated in Section 9.5.2. For pregnancies that end < 24 weeks gestation among participants who do not have CE and are not randomised, the End of Pregnancy Assessment will be the final follow up. These participants will **not** revert back to telephone follow-up as stated in Section 9.5.1.

* These assessments may be conducted by telephone unless there is a clinical need for participants to be seen in hospital.

9.10 Payment

There are no payments for participation in this trial. We will reimburse hospital parking charges when women attend for their biopsy and to collect the IMP.

10. PHARMACOVIGILANCE

10.1 Definitions

Term	Definition
Adverse Event (AE)	Any untoward medical occurrence in a participant to whom a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product.
Adverse Reaction (AR)	<p>An untoward and unintended response in a participant to an investigational medicinal product which is related to any dose administered to that participant.</p> <p>The phrase "response to an investigational medicinal product" means that a causal relationship between a trial medication and an AE is at least a reasonable possibility, i.e. the relationship cannot be ruled out.</p> <p>All cases judged by either the reporting medically qualified professional or the Sponsor as having a reasonable suspected causal relationship to the trial medication qualify as adverse reactions. It is important to note that this is entirely separate to the known side effects listed in the SmPC. It is specifically a temporal relationship between taking the drug, the half-life, and the time of the event or any valid alternative etiology that would explain the event.</p>
Serious Adverse Event (SAE)	<p>A serious adverse event is any untoward medical occurrence that:</p> <ul style="list-style-type: none"> • results in death • is life-threatening • requires inpatient hospitalisation or prolongation of existing hospitalisation • results in persistent or significant disability/incapacity • consists of a congenital anomaly or birth defect <p>Other 'important medical events' may also be considered serious if they jeopardise the participant or require an intervention to prevent one of the above consequences.</p> <p>NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.</p>
Serious Adverse Reaction (SAR)	An adverse event that is both serious and, in the opinion of the reporting Investigator, believed with reasonable probability to be due to one of the trial treatments, based on the information provided.
Suspected Unexpected Serious Adverse Reaction (SUSAR)	<p>A serious adverse reaction, the nature and severity of which is not consistent with the information about the medicinal product in question set out in the reference safety information (RSI):</p> <ul style="list-style-type: none"> • Section 4.8 of the SmPC Doxycycline 100mg Capsules. The version of this document being used as the trial's RSI

	<p>and will be supplied in the investigator and pharmacy site file. The Electronic Medicines Compendium (EMC) will be checked for updates made to the SmPC, every 6 months by the trial team. Any changes to the SmPC will be reviewed by the CI and Sponsor Pharmacy Advisor. If a change in the SmPC information is deemed necessary to update the trials RSI this will be actioned via a substantial amendment.</p> <ul style="list-style-type: none"> • The Manual For Collection of Endometrial Biopsies will be used to assess expectedness of events related to trial endometrial biopsy.
--	---

NB: "Severe" is often used to describe intensity of a specific event, which may be of relatively minor medical significance. "Seriousness" is the regulatory definition supplied above.

10.2 Operational definitions for AEs/SAEs

We will follow WCTU's SOP on 'Safety Reporting' for all Adverse Events (AE) and Serious Adverse Events (SAE).

Exemptions from AE/SAE reporting

The following events listed in Table 10 will not be reported as AEs or SAEs (if hospitalisation is required) as they will be reported and recorded as part of trial efficacy outcomes and are common AEs/SAEs in this population. Comparative rates of these events will be monitored by the DMC:

Table 10 – Events collected via CRF exempt from AE/SAE reporting

Condition
Admission to hospital for miscarriage (<24 weeks)
Admission to hospital for stillbirth (≥24 weeks)
Admission to hospital for a molar pregnancy
Admission to hospital for an ectopic pregnancy
Fetal growth problems / admission to hospital for fetal growth problems
Admission to hospital for unstable lie
Admission to hospital for delivery
Admission to hospital for delayed delivery
Admission to hospital for threatened pre-term labour
Admission to hospital for pre-term birth
Admission to hospital for Caesarean section
Congenital abnormality or birth defect*

* If a participant reports she has a positive pregnancy test whilst taking the doxycycline/placebo or has a positive pregnancy test within 4 weeks of stopping the doxycycline/placebo she would have conceived in the cycle she took the medication and

therefore this AE/SAE reporting exemption does not apply. SAEs should be reported as per 10.3.2.

If treatment or intervention is required following a medical complication that fulfils the criteria for a SAE i.e. is life-threatening or prolongs hospitalisation for any of the events listed in Table 10 then a SAE should be reported. For any of the events listed in Table 10 prolonged hospitalisation is defined by the following:

- ≥ 4 days for a pregnancy < 24 weeks
- ≥ 7 days for a pregnancy ≥ 24 weeks

In addition some events that would meet a definition of a serious adverse event; for example admission to hospital due to nausea and vomiting, headaches or vaginal bleeding are relatively common in pregnancy. SAEs that **do not** require time critical reporting but should be recorded as AEs on the Adverse Event Form are listed in Table 11:

Table 11 – Adverse Events exempt from SAE reporting but still recorded as AEs

Condition
Admission to hospital for nausea and vomiting
Admission to hospital for headaches
Admission to hospital for raised blood pressure
Admission to hospital for urinary tract infection
Admission to hospital for vaginal bleeding
Admission to hospital for pregnancy induced hypertension

10.3 Recording and reporting of AEs SAEs, SARs AND SUSARs

AEs and SAEs will be collected from the time of written consent for registration until 30 days post last trial treatment (last capsule taken). For participants who do not have CE or are not randomised AEs and SAEs will only be collected until 30 days post biopsy. For CERM B patients AEs should be collected until 30 days post repeat biopsy/swabs.

10.3.1 Recording of Adverse Events

All AEs (except those specified in table 10) that occur in the participant should be recorded on an Adverse Event Form and in the participants' medical notes.

If the AE is ongoing at the time of reporting then any change to the condition or outcome of the event should be reported on an Adverse Event Follow-up Form.

30 days after the participant has completed their treatment, or 30 days after biopsy for non randomised participants or repeat biopsy/swabs for CERM B patients, there is no requirement for the hospital research team to identify any new AEs. For randomised participants however, if the hospital research team become aware of an SAE that has occurred post 30 days since

last treatment received and the Investigator considers the SAE to be related to doxycycline/placebo, then the Investigator should report the SAE.

Adverse Event data will be reviewed by the CERM TMG and by the DMC.

10.3.2 Reporting SAEs and SUSARs

All SAEs/SUSARs that occur must be recorded on the Serious Adverse Event Form and emailed to **cerm@warwick.ac.uk** within **24 hours** of the research staff becoming aware of the event. Once all resulting queries have been resolved, WCTU will request the original form be posted to the WCTU and a copy to be retained on site.

For each **SAE/SUSAR** the following information will be collected:

1. full details in medical terms and case description
2. event duration (start and end dates, if applicable)
3. outcome
4. severity assessment
5. causality (relatedness to trial drug), in the opinion of the investigator
6. whether the event would be considered expected.

Any change of condition or other follow-up information should be emailed to **cerm@warwick.ac.uk** using the Serious Adverse Event Follow-Up form as soon as it is available or at least within 24 hours of the information becoming available. Events will be followed up until the event has resolved or a final outcome has been reached.

The causality of SAEs (i.e. relationship to trial treatment/intervention) will be assessed by both the investigator(s) and the CI (or their medical delegate) on the SAE form. These assessments will be independent of each other.

Table 12 – SAE Causal relationship

Relationship to trial medication	Description
Unrelated	There is no evidence of any causal relationship
Unlikely to be related	There is little evidence to suggest there is a causal relationship (e.g. the event did not occur within a reasonable time after administration of the trial medication or device). There is another reasonable explanation for the event (e.g. the participant's clinical condition, other concomitant treatment).
Possible relationship*	There is some evidence to suggest a causal relationship (e.g. because the event occurs within a reasonable time after administration of the trial medication or device). However, the influence of other factors may have contributed to the event

	(e.g. the participant's clinical condition, other concomitant treatments).
Probable relationship*	There is evidence to suggest a causal relationship and the influence of other factors is unlikely.
Definitely related*	There is clear evidence to suggest a causal relationship and other possible contributing factors can be ruled out.

If there is a possible, probable or definite relationship to the intervention/treatment, then an assessment of expectedness must also be completed by a member of the CERM trial team at WCTU and authorised by the CI or medically qualified delegate on the SAE form. Causality must be assessed by a medical member of staff at the recruiting site who has been delegated this responsibility on the trial delegation log.

The CI or delegate will have the discretion to upgrade any events that require escalation, but will not be able to downgrade any clinical opinion made at site.

Section 4.8 of the SmPC relevant to the doxycycline/placebo will be used to assess expectedness of events related to trial treatment. Up to date versions of the relevant SmPC will be monitored by WCTU CERM Trial Team. Any updated SmPC will be sent to the MHRA for approval prior to use in the trial.

The Manual For Collection of Endometrial Biopsies will be used to assess expectedness of events related to trial endometrial biopsy.

All SAEs assigned by the CI or delegate as both suspected to be related to IMP treatment/biopsy and unexpected will be classified as SUSARs and will be subject to expedited reporting to the Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee as required.

SAEs deemed to be SUSARs will be reported to the REC/MHRA within the specified timelines according to UK legislation (i.e. 7 days for fatal/life threatening events and 15 days for other 'serious' categories).

WCTU will inform the Sponsor, MHRA and the REC of SUSARs within the required expedited reporting timescales.

The trial manager will liaise with the investigator to compile all the necessary information.

Participants are followed up throughout their pregnancy. Details of the trial follow-up duration are given in the CERM Trial summary table 5.

10.4 Responsibilities

Principal Investigator (PI):

Checking for AEs and ARs when participants attend for treatment / contacted for follow-up.

1. Using medical judgement in assigning causality. Grading each adverse event using CTCAE.

2. Ensuring that all SAEs are recorded and reported to the sponsor within 24 hours of becoming aware of the event and provide further follow-up information as soon as available. Ensuring that SAEs are chased with WCTU if a record of receipt is not received within 2 working days of initial reporting.
3. Ensuring that AEs and ARs are recorded and reported to the sponsor in line with the requirements of the protocol.

Chief Investigator (CI) / delegate or independent clinical reviewer:

1. Clinical oversight of the safety of patients participating in the trial, including an ongoing review of the risk / benefit.
2. Using medical judgement in assigning the SAEs causality.
3. If related, assessing whether and event/reaction was expected in line with the Reference Safety Information / protocol assisted by Trial Manager/Coordinator.
4. Immediate review of all SUSARs.
5. Review of specific SAEs and SARs in accordance with the trial risk assessment and protocol as detailed in the Trial Monitoring Plan.
6. Preparing the clinical sections and final sign off of the Development Safety Update Report (DSUR).

WCTU:

1. Central data collection and verification of AEs, ARs, SAEs, SARs and SUSARs according to the trial protocol onto a database.
2. Conduct expectedness assessment in conjunction with the CI on SARs using the approved Reference Safety Information/protocol.
3. Reporting safety information to the CI, delegate or independent clinical reviewer for the ongoing assessment of the risk / benefit according to the Trial Monitoring Plan.
4. Reporting safety information to the independent oversight committees identified for the trial (Data Monitoring Committee (DMC) and / or Trial Steering Committee (TSC)) according to the Trial Monitoring Plan.
5. Expedited reporting of SUSARs to the Competent Authority (MHRA in UK) and REC within required timelines.
6. Notifying Investigators of SUSARs that occur within the trial.
7. The unblinding of a participant for the purpose of expedited SUSAR reporting.
8. Checking for (bi-annually) and notifying PIs of updates to the Reference Safety Information for the trial.
9. Preparing standard tables and other relevant information for the DSUR in collaboration with the CI and ensuring timely submission to the MHRA and REC.

Trial Steering Committee (TSC):

In accordance with the trial TSC charter, periodically reviewing safety data and liaising with the DMC regarding safety issues.

Data Monitoring Committee (DMC):

In accordance with the trial DMC charter, periodically reviewing overall safety data to determine patterns and trends of events, or to identify safety issues, which would not be apparent on an individual case basis.

10.5 Notification of deaths

All deaths will be reported to the Sponsor irrespective of whether the death is related to the IMP, or an unrelated event.

10.6 Reporting urgent safety measures

If any urgent safety measures are taken the CI/Sponsor shall immediately and in any event no later than 3 days from the date the measures are taken, give written notice to the MHRA and the relevant REC of the measures taken and the circumstances giving rise to those measures.

10.7 Development safety update reports

WCTU will prepare and submit DSURs once a year throughout the clinical trial, or as necessary to the MHRA and REC. This report will detail any new safety data received during the reporting period. The report will be submitted within 60 days of the Developmental International Birth Date (DIBD) of the trial each year until the trial is declared ended.

11. TISSUE SAMPLES

11.1 Endometrial Biopsies

Endometrial biopsies will be sent to the central laboratory at University Hospitals Coventry and Warwickshire (UHCW) and should be collected, shipped and tracked in accordance with the CERM A Manual for collection of Endometrial Biopsies.

In some women taking the endometrial biopsy can be painful and may cause cramping at the time of the biopsy. Taking Paracetamol and Ibuprofen an hour before the biopsy can help with this. If needed gas and air (Entonox) is available while having the biopsy. In some women, spotting may happen after the biopsy is taken, this will resolve quickly on its own.

The healthcare professional will do all they can to make sure they collect enough endometrial tissue to be analysed, but in a few cases this may not be possible. If the healthcare professional is not able to collect a sample or cannot collect enough tissue to be analysed, the health professional carrying out the biopsy will discuss the following options with the woman;

- The same healthcare professional will repeat the biopsy during the same appointment
- A different healthcare professional will take the biopsy during the same appointment
- Return to the clinic for another biopsy during the next menstrual cycle *
- Have a biopsy taken at UHCW *

*The woman will need to complete another screening consent form In the event of these options.

A maximum of two biopsy samples should be obtained per patient for the initial endometrial biopsy. If results are not obtained from the second endometrial biopsy sample then the women will not be able to enter the trial.

For CERM B patients only one endometrial biopsy sample and one set of swabs should be obtained for the repeat biopsy following treatment.

11.1.2 Analysis of endometrial biopsies

Once received UHCW laboratory will set the tissue sample in a wax block for analysis. Technicians preparing the biopsies will be competent to do so by virtue of their regular clinical work and will additionally be given training in the Standard Operating Procedure for the CERM Trial.

Guidance on the laboratory processing of tissue samples can be found in the CERM A Manual for processing, staining, analysis, and reporting of endometrial biopsy samples.

Chronic Endometritis will be diagnosed based on the density of CD138 staining cells within a tissue section. This methodology was derived from previously published material³⁶ and in advance of this trial it has been externally validated for the trial by experts in the field. The endometrial sample will be embedded in paraffin wax and sectioned onto slides. The slides will be stained with CD138 mouse monoclonal antibody. These will then be reviewed and the

density calculated by trained observers following a standard operating procedure to ensure consistency. Borderline samples will be counted by two observers. The process will be both internally and externally quality assured as outlined in the trial document: CERM Trial: Analysis and Reporting of Endometrial Biopsy Samples Standard Operating Procedure. A positive screen will be defined as ≥ 5 CD138 positive cells per 10mm^2 . Samples will be reported as screen positive or negative to allow progression to randomisation. Exact counts will be kept to allow sub-group analysis of the data at a later stage.

Counting will be performed by trained members of the trial team who will have undergone an extensive training presentation and will be continually quality assured both internally and externally.. Technicians will follow the CERM A Manual for processing, staining, analysis, and reporting of endometrial biopsy samples.

11.1.3 Results of endometrial biopsy samples

Biopsy results will be emailed to sites within four weeks of receipt at the central laboratory.

11.2 Microbial swabs

For participants registered for CERM B a microbial swab of the vagina, endometrium and cervix will be taken and sent to Imperial College London for analysis in special containers. Clinicians taking swabs will be competent to do so either by virtue of clinical role and training or appropriate specialist training on the technique for the trial. Clinicians will follow the CERM B Manual for collection of Microbial Swabs.

11.2.1 Analysis of the microbiome

Vaginal, endometrial and cervical swabs before and after treatment will be sent to Imperial for exploratory analysis of the endometrial microbiome. These paired samples will be labelled with:

- Trial ID number
- Patient Initials

Details of the preparation of the swabs and analysis is in the SOP for microbiome analysis. Microbiologists undertaking the analysis of swabs will be doing so commensurate with their role having previously undergone relevant training in the area.

In some cases there may be tissue left over following analysis, with the women's permission, we will keep this tissue and clinical data for future research studies into pregnancy loss. The tissue will be stored anonymously in the Tommy's reproductive health bio-bank and kept strictly in accordance with The Human Tissue Act 2004.

12. STATISTICS AND DATA ANALYSIS

12.1 Sample size

12.1.2 Sample size – screening trial

The target sample size for the screened participants is 3,062.

12.1.3 Sample size - randomised controlled trial

The target sample size is 1,500, 750 women in the intervention arm (doxycycline) and 750 women in the control arm (placebo).

The total number of women recruited to the screening part of trial will be determined by the proportion eligible for the randomised controlled trial. Our current assumptions suggest as overall recruitment of around 3,062 women over 24 months with 1,500 women in the randomised trial.

Based on the target size of 1500, the simulations used here include 2 scenarios of the treatment effect. First, the 'Target' scenario, assuming 48% incidence of ongoing pregnancy (at 12+6 weeks) in the control arm and 56% in the intervention arm (an 8% difference). Secondly, the 'Null' scenario, where both trial arms have 48% incidence of ongoing pregnancy at 12+6 weeks (no difference). Simulations included three planned interim analyses, when 100 and 300 and 900 women in total will have been randomised and followed up for 28 weeks. Stopping early for futility ('No Benefit') is an option for all three interim analyses but stopping early for efficacy ('Success') is allowed at the third interim analysis only.

The stopping criteria at all interim analyses are defined as:

- Lack of benefit: Posterior probability that intervention is better than control is lower than 0.05
- Success: Posterior probability that intervention is better than control is higher than 0.995
- At the final analysis, "success" is a Posterior probability that intervention is better than control higher than 0.975.

Using these stopping criteria, the study achieves statistical power of 92% with type I error at 5%.

All results are based on 5000 simulations. (Also 5000 simulations for the Monte Carlo for the difference of the two posterior probabilities, intervention – control to check for the stopping criteria). Parameters for beta prior of response for either group: $\alpha=0.5$, $\beta=0.5$. The values for stopping for efficacy, futility and success were chosen based on type I and type II errors, considering as null hypothesis that the intervention is not better than the control.

For the scenario of 'No Benefit', when there is no difference between the arms, 11.16% of trials stopped early for No Benefit (correct decision) and only 0.56% stopped early for Success (type I error, incorrect decision). In this case, the average sample size was 1375 women. For the 'Target' scenario 43.24% of trials correctly stopped for Success and only 0.74% stopped

early for No benefit (type II error). The average sample size under this treatment effect was 1230 women (Table 13).

Table 13: Simulated Results for Power Calculations implementing Target and No Benefit Scenario

	Decision Successful	Decision No Benefit	Stop early for Success - Interim 3	Stop early for No Benefit- Interim 1	Stop early for No Benefit- Interim 2	Stop early for No Benefit- Interim 3
Target	0.92	0.08	0.4324	0.006	0.0014	0
Null	0.05	0.95	0.0056	0.0454	0.034	0.0322
Type I error	0.05					
Type II error	0.08					

12.2 Stratification

Randomisation: Women will be randomised to placebo or doxycycline. Minimisation will be by age (<35 vs ≥35 years), number of previous miscarriages (≤3 vs >3) and site.

12.3 Statistical analysis

The primary analysis will be conducted by intention to treat (ITT). The treatment difference will be compared between the participants randomised to placebo and doxycycline. The primary outcome, total live births plus ongoing pregnancies at ≥24 + 0 weeks gestation at the end of the trial, will be analysed using logistic regression models.

Secondary analysis will be conducted in a similar approach. The treatment effect will be compared to assess the categorical and continuous secondary outcomes using logistic and linear models, respectively.

Mediation analysis will be carried out to investigate whether any treatment effect on the total number of live births is mediated by conception, early miscarriage, or late miscarriage.

The results will be reported as odds ratio (OR) with 95% confidence interval (CI) for categorical outcomes and mean difference with 95% CI for continuous outcomes. The analysis will be conducted in an unadjusted and adjusted way, with adjustment for the stratification variables and important covariates. Missing data for the primary outcome are likely to be minor. However, if the missing primary outcome data exceeds 20%, imputation techniques will be employed and the imputed data will be used as a sensitivity analysis.

Treatment effect will also be assessed in the following subgroup for exploratory purpose:

1. Age (<35 vs ≥35)
2. Severity of chronic Endometritis:
 - a. Mild (5-20 CD138 cells)
 - b. Moderate (21-200 CD138 cells)
 - c. Very high (201+ CD138 cells)
3. number of previous miscarriages (≤3 vs >3)

The interaction between the subgroup variable with treatment will be tested and the overall significance of the interaction will be reported.

12.3.1 Interim analysis

Adaptive trial approach using the on-going pregnancy rate for efficient trial design Instead of a fixed trial design, we will use interim analyses to look at the data during recruitment and allow early stopping if it is likely that the trial will be inconclusive, or it is already clear that the intervention is effective or harmful.

A detailed statistical analysis plan (SAP) will be developed by the trial statistician and approved in line with the WCTU SOP requirements.

12.3.2 Final analysis

For the purposes of the final analysis, treatment success is defined as the difference in birth rate of any magnitude favouring doxycycline with probability of no less than 97.5%.

13. DATA MANAGEMENT

Personal data collected during the trial will be handled and stored in accordance with the General Data Protection Regulation (GDPR) and Data Protection Act 2018. UHCW and WCTU at the University of Warwick (UoW) will act as joint data controllers for this trial. UHCW, UoW and Imperial College London will also act as Data Processors (as defined in GDPR).

13.1 Data collection tools and source document identification

13.1.1 Database

The database will be developed by the Programming Team at WCTU. All specifications (i.e. database variables, validation checks,) will be agreed between the programmers and appropriate WCTU trial staff. The electronic case report forms (eCRFs) will be designed by the Chief Investigators, Trial Manager, Medical Statistician, Programmers and representatives from obstetric units.

13.1.2 eCRF completion

CERM will use a remote electronic data capture system. All data will be directly entered onto eCRFs in the trial database by site staff from the source data (e.g. hospital records, participant medical notes, laboratory records and clinical reports). Data can only be entered by staff who are listed on the site staff delegation log and authorised by the PI to perform this duty. Access to the database is restricted by username and password. All data submitted on eCRFs must be verifiable in the source documentation. Any deviation from this must be explained appropriately.

When collecting data during verbal conversations with participants, please ensure that relevant details of the conversation are fully detailed in source documents. This will enable the corresponding eCRF data to be verified against the source documents. If an inconsistency is identified between data obtained during verbal discussions and data in existing source documents, details of the discrepancy should be documented with a clear justification for which source is deemed accurate.

13.1.3 Missing data

All fields MUST be completed. If data are unavailable because a test or measurement was not done, please indicate why that was omitted on the eCRF. Data should be corrected at site if any errors are made. Upon correcting data staff will be asked to specify the reason for the correction. An explanatory note should be added if necessary.

13.1.4 Timelines for eCRF completion

eCRFs must be completed in a timely manner as soon as possible after the trial visit/assessment. Procedures for chasing missing eCRFs and data will be detailed in the CERM Data Management Plan.

13.1.5 Data quality

Data entered into the trial database will be checked for accuracy and completeness in accordance with the trial data management plan.

13.1.6 Post randomisation withdrawals and exclusions

In accordance with the Declaration of Helsinki, each participant is free to withdraw from the research trial at any time (including follow-up) without providing a reason and without prejudice, if they so wish. Women are informed of their rights in the participant information sheet. Unless a woman explicitly withdraws their consent, they and their infant will be followed-up wherever possible and data collected as per the protocol until the end of the trial.

The reason for withdrawal will be recorded in the Case Report Form (CRF). If the reason for withdrawal is an Adverse Event (AE), monitoring of the participant will continue until the outcome is evident. The specific event will be recorded in a CRF.

If participants deliver their baby in a different trust to the trust they were consented at, please contact the research team at the relevant NHS organisation to obtain medical details in relation to this research trial.

13.2 Data handling and record keeping

All data will be stored securely and held in accordance with the relevant UK data protection legislation. Data will be entered on-line onto the secure password protected trial database and accessible only by authorised members of the team.

Participant identification data will be required for the registration process. WCTU will preserve the confidentiality of participants taking part in the trial.

Participant confidentiality will be ensured by using a trial identification number to identify a participant. Sites will maintain a participant enrolment log linking the participant's name to their trial identification number. This list will only be accessible to authorised members of the trial team. Participant case notes and files may be inspected by members of WCTU, Sponsor and other regulatory bodies as required (written consent for this will be sought as part of the informed consent process).

Any data or samples transferred from the site will be identified by the trial identification number and patient initials only.

Participants will not be identified in any trial reports or publications.

13.3 Access to data

All trial related documentation will be stored in accordance with all applicable regulatory requirements and access restricted to authorised personnel.

Participant data at the offices of WCTU will be kept in individual participant files (identified only by trial identification number and patient initials) in filing cabinets in locked offices accessible only to authorised members of the CERM trial team.

Access to the databases will be restricted to authorised personnel only including representatives from WCTU, the sponsor and the regulatory authorities to permit trial-related monitoring, audits and inspections - in line with participant consent.

13.4 Data archiving

At WCTU the trial master file will be archived for 25 years upon publication of the final clinical study report.

UHCW and the WCTU will keep identifiable information for the following length of time after the trial has published the final clinical report:

- 10 years If a participants biopsy shows that you they do not have endometritis
- 25 years if the results of a participants biopsy show that they do have endometritis.

All data archived at WCTU will be done so in accordance with WCTU SOP 23 'Data Archiving'.

At site the PI or designee must maintain adequate and accurate records to enable the conduct of the Trial to be fully documented and the Trial data to be subsequently verified. After trial closure the PI will maintain all source documents and trial related documents.

All source documents will be retained following the end of the Trial for a minimum period of:

- 10 years If a participants biopsy shows that you they do not have endometritis
- 25 years if the results of a participants biopsy show that they do have endometritis

The Investigator and Pharmacy Site File must be archived for a minimum of 25 years. WCTU will authorise and advise of the archiving requirements as part of the site closure process (on behalf of the Sponsor).

14. TRIAL OVERSIGHT

14.1 Role and responsibilities of the Sponsor

University Hospitals Coventry and Warwickshire NHS Trust, Clifford Bridge Road, Coventry CV2 2DX, will act as Sponsor for the trial and undertake the responsibilities as defined by the UK Policy Framework For Health and Social Care Research and ICH Good Clinical Practice. An authorised representative of the Sponsor has approved the final version of this protocol with respect to the trial design, conduct, data analysis and interpretation and plans for publication and dissemination of results.

Trial management will be undertaken at Warwick Clinical Trials Unit, the University of Warwick, Coventry, CV4 7AL. A sub-contract agreement is in place between UHCW and WCTU who will provide full research management services. This will specify whose SOPs will be adhered to for each aspect of the trial.

Clinical Trial Agreements will also be in place between the Sponsor and each research site, with clear delegation of roles and responsibilities.

14.1.1 Indemnity

‘NHS indemnity covers NHS staff, medical academic staff with honorary contracts and those conducting the trial. NHS bodies carry this risk themselves or spread it through the Clinical Negligence Scheme for Trusts, which provides unlimited cover for this risk. Negligent harm cover will be provided by standard NHS arrangements. NHS Indemnity does not give indemnity for compensation in the event of non-negligent harm, so no specific arrangements exist for non-negligent harm for this trial’. The University of Warwick Clinical Trials Unit has a Clinical Trials Insurance Policy, Professional indemnity and legal liability insurance in place to cover the CERM trial.

14.2 Role and responsibilities of the Funder

Funding for this trial is provided by the Efficacy and Mechanism Evaluation Programme (EME), an MRC and NIHR partnership. The design and management of this trial are entirely independent of the funder.

14.3 Trial management arrangements

14.3.1 Trial Management Group

The Trial Management Group (TMG) comprises co-investigators, allied experts and trial management staff and is responsible for the day-to-day running of the trial (Table 1). Significant issues that may arise will be reported by the Chair to the Trial Steering Committee and / or Data Monitoring Committee (DMC) and the Sponsor. The TMG will meet monthly throughout the trial and will invite key staff from collaborating and external organisations and investigators from participating sites as required.

The TMG Charter will specifically detail the membership, responsibilities and purpose of the TMG.

14.3.2 Trial Steering Committee

The Trial Steering Committee (TSC) comprises independent lay members, experts in biostatistics, health and clinical epidemiology and obstetrics and gynaecology (Table 2). The TSC will approve the final trial protocol, advise on all aspects of the trial conduct, monitor trial progress, review relevant information from other sources, consider recommendations from the DMC and advise on protocol amendments. They will assess recruitment after 250 patients have been randomised, and will consider modification or termination of the trial (in consultation with the DMC) in the event of poor recruitment. They will meet regularly throughout the trial and not less than once a year.

The TSC Charter will specifically detail the membership, responsibilities and purpose of the TSC.

14.3.3 Data Monitoring Committee

The Data Monitoring Committee (DMC) comprises independent experts with relevant clinical research, and statistical experience. (Table 3). They will ensure close monitoring of outcomes and safety aspects during the trial.

Confidential reports containing recruitment, protocol compliance, safety data and interim assessments of outcomes will be reviewed by the DMC. The DMC will advise the TSC as to whether there is evidence or reason why the trial should be amended or terminated.

DMC meetings will also be attended by the Chief Investigator and Trial Manager (for non-confidential parts of the meeting) and the trial statistician. They will meet regularly throughout the trial and not less than once a year.

The DMC Charter will specifically detail the membership, responsibilities and purpose of the DMC.

14.3.4 Investigator meetings

Investigator meetings will be held during recruitment and key staff from participating sites will be invited. The meetings will review trial progress, recruitment and discuss any emerging issues.

14.3.5 Essential documentation

A Trial Master File will be set up in accordance to WCTU SOP 11 - 'Essential Documentation' and held securely at WCTU. Investigator Site Files and pharmacy files will be prepared and distributed to participating trial sites by WCTU where possible or the content for the investigator site files and pharmacy files will be uploaded to the trial website (<https://warwick.ac.uk/cerm>) for sites to download.

14.3.6 Warwick CTU CERM trial team

Warwick Clinical Trials Unit CERM trial team will have responsibility for overseeing day to day coordination of the trial and reporting regularly to the TSC. The WCTUs trial management responsibilities include, but are not limited to:

- Coordinating protocol development, participant and trial management documents
- Correspondence with trial funder and tracking of progress against agreed milestones
- Setting up and maintaining the Trial Master File;
- Ensuring necessary approvals are in place before the start of the trial at each site;
- Submitting amendments to the MHRA and REC and disseminating these to sites
- Providing training to trial personnel;
- Providing data management support; including data input, maintenance of the trial database and raising of queries
- Producing trial progress reports and coordinating TSC meetings and minutes;
- Ensuring data security and quality and ensuring data protection laws are adhered to;
- Ensuring complete records are in place for audit and monitoring purposes;
- Ensuring the trial is conducted in accordance with the ICH GCP;
- Monitoring, recording, reporting and resolving any non-compliance with the protocol or GCP
- Archiving all original trial documents including the data forms in line with WCTU SOPs”

15.4 Trial registration

The trial’s International Standard Randomised Controlled Trial Number is ISRCTN23947730 and EudraCT number is 2019-000585-38.

15. MONITORING, AUDIT & INSPECTION

The trial will be monitored and audited by Warwick Clinical Trials Unit, as representatives of the sponsor, in accordance with WCTU procedures to ensure that the trial is being conducted as per protocol, adhering to Research Governance and GCP. The Sponsor will perform a co-monitoring visit at their own site UHCW.

The approach to, and extent of, monitoring will be specified in a trial monitoring plan determined by the risk assessment undertaken prior to the start of the trial. The Risk Assessment and Monitoring Plan will be updated as appropriate during the trial if there is a change to the trial's risk profile.

15.1 Training

The Chief Investigator has completed chief investigator training course and courses on handling and storing of human tissue.

A programme of trial specific training will be provided to all clinicians, staff participating in the trial, and PPI as required including: the principles of Good Clinical Practice, the importance of the trial, background, the trial protocol, inclusion and exclusion criteria, ethical issues and consent, randomisation procedures, data collection, documentation and completing and maintaining training logs. It is the PI's responsibility to ensure that all site staff are trained appropriately and documented on the delegation log. Site staff not present for the site initiation visit as a minimum will be required to read the trial protocol. This will be documented in the Investigator Site File in section 10.1. If site staff require training by the CERM trial team please email cerm@warwick.ac.uk to request this.

All new WCTU staff will complete a trial induction and training programme.

PPI members will also be offered a place on the CTU training day entitled '*Being Part of a Research Team*' <https://warwick.ac.uk/ppitrianing>.

15.2 Quality assurance

A risk assessment will be undertaken and will form the basis of the trial monitoring plan. Sites will be visited during the recruitment period to audit the quality of the trial process and documentation. Additional site visits may be required, if triggered by issues raised as documented in the monitoring plan.

15.3 Visits to sites

The trial will be monitored and audited in accordance with WCTU procedures. All trial related documents will be made available on request for monitoring and audit by WCTU, UHCW, REC and for inspection by the MHRA or other relevant bodies. Prior to the trial start, the PI will be advised of the anticipated frequency of the monitoring visits. The PI and site R&D department (if applicable), will receive reasonable notification prior to each monitoring visit.

During an on-site or remote monitoring visit the WCTU monitor/trial manager will review trial records and compare them with source documents, discuss the conduct of the trial and any

emerging problems with the PI (or designee), check that the drug storage, dispensing and retrieval are reliable and appropriate and verify that the available facilities remain acceptable.

The PI will allow WCTU direct access to relevant source documentation for verification of data entered onto the CRFs taking into account data protection regulations. Entries in the CRF will be compared with participants' medical records and the results will be documented in a monitoring report form. The WCTU monitor/trial manager should also be given access to other relevant departments (i.e. pharmacy) and relevant trial staff should be available to meet as required.

The participants' medical records and other relevant data may also be reviewed by appropriate qualified personnel independent from the WCTU appointed to audit the trial, and by regulatory authorities. Details will remain confidential and participants' names will not be recorded outside the hospital.

Following a monitoring visit the WCTU monitor/trial manager will send a copy of the monitoring report to the PI at site, other relevant trial staff and the trial Sponsor. The PI will be given appropriate time to provide a written response to the findings listed on this report. The response will be considered by the Sponsor to determine if adequately addresses the issues identified.

During the COVID-19 pandemic onsite monitoring may not be possible. Instead monitoring oversight may need to be performed remotely via telephone or video. Where capacity at each site allows, self-monitoring checklists will be used as an additional monitoring strategy.

16. ETHICAL AND REGULATORY CONSIDERATIONS

16.1 Ethical approval and research governance

The trial will be conducted in full conformance with the principles of the Declaration of Helsinki, ICH Good Clinical Practice (GCP) guidelines and the UK Statutory Instrument Number 1031 that implements the Medicine for Human Use (Clinical Trials) Directive 2004 and subsequent amendments. All data will be stored securely and held in accordance with Data Protection Act 2018.

A Clinical Trial Authorisation will be obtained from the UK Competent Authority the Medicines and Healthcare products Regulatory Agency (MHRA), favourable opinion from a Research Ethics Committee and Health Research Authority (HRA) approval. All required ethical and regulatory approval(s) for the trial will be sought using the Integrated Research Application System. The CERM trial is part of the HRA and MHRA combined ways of working pilot. Before enrolling participants into the trial, capacity and capability assessment and approval from each relevant NHS Trust Research & Development (R&D) departments must be obtained by the Warwick Clinical Trials Unit CERM Trial Team and an official site opening letter issued.

Substantial protocol amendments will be provided to Principal Investigators and site staff and other relevant parties once the appropriate approvals have been obtained.

Annual reports will be submitted to the REC within 30 days of the anniversary date on which the favourable opinion was given, and annually until the trial is declared ended. The REC and the MHRA will be notified of the end of the trial (whether at planned time or prematurely).

The Chief Investigator will submit a final report to the required authorities with the results, including any publications within one year of the declared end of the trial.

16.2 Ethical considerations for women participating in CERM

In any trial involving women trying to conceive, consideration is needed on the ethical aspects of the trial. In this trial there is a paradox; to help women to have a baby we are asking them to use contraception for up to four menstrual cycles: biopsy preparation, biopsy, screening and if they screen positive, randomisation (figure 5). This may be a difficult decision, considering the majority of women will not receive active medication, and especially difficult for women with sub-optimal fertility. Therefore it is important to minimise the time women are using contraception by streamlining the participant journey and trial processes.




Figure 5 – CERM participant journey

If a women reports unprotected sexual intercourse or a condom failure, in the month prior to her biopsy, the biopsy will be cancelled and she will have to wait for her next menstrual cycle and prepare for the biopsy again; If this happens it will further delay conception and this may

be distressing and or frustrating for some women. If a women conceives following unprotected sexual intercourse or a condom failure she will follow the pregnancy care pathway and be referred to her GP who will arrange her care.

Women who screen negative for CE may be disappointed that a possible cause for their RMs has not been identified. They will return to the usual care pathway but if they have consented at screening they will be contacted and data will be collected on any first pregnancies within 12 months of their negative CE diagnosis.

To try to reduce distress and or frustration and ensure the risks are clearly stated our PPI co-applicant is leading on the development of all participant facing materials, together with the research team.

The participant information sheets and participant information leaflet, have been reviewed and revised by editors from the Plain English Campaign and they have all received a Crystal Mark. We will also develop a web-based resource for women with more detailed information available from the trial website <https://warwick.ac.uk/cerm>.

Women will be given as much time as they need to consider participating in the trial and have the opportunity to discuss participation and ask questions with specially trained clinicians including obstetricians, research midwives and unit midwives.

We will ensure that all identifiable data is anonymised and treated as confidential. All data will be stored securely and held in accordance with all applicable UK legislation and WCTU Standard Operating Procedures (SOPs).

16.3 Notification of Serious Breaches to GCP and/or the protocol

“A ‘serious breach’ will be defined as a deviation from the protocol or GCP that is likely to effect to a significant degree:

1. The safety or physical or mental integrity of the subjects of the trial; or
2. The scientific value of the trial

WCTU will be notified immediately of any case where the above definition applies during the trial conduct phase. In accordance with the WCTU SOP 31 ‘Deviations, Violations, Misconduct and Serious Breaches of GCP and/or Study Protocol’ WCTU will notify the licensing authority in writing of any serious breach of:

1. The conditions or principles of GCP in connection with the trial; or
2. The trial protocol, as amended time to time, within 7 days of becoming aware of the breach

16.4 Patient and Public Involvement

16.4.1 The Lily-Mae Foundation

The Lily-Mae Foundation (<https://www.lilymaefoundation.org>), a leading charity supporting parents and families after pregnancy loss. A co-founder of the charity is a co-applicant and has been involved in the planning and development of this trial. They will be involved in all

aspects of trial management and attend monthly TMG meetings. They will lead on the development of all the patient facing materials including the patient information sheets, patient information booklet, consent forms, trial poster and the content of the participant area of the trial website. This will ensure the clarity of the information given to participants.

16.4.2 The Tommy's Charity

A PPI member from the Tommy's Charity and Miscarriage Association will sit on the TSC.

A training course will be provided for PPI members to cover all trial related activities (<https://warwick.ac.uk/ppitraining>).

17. DISSEMINATION AND PUBLICATION

The results of the trial will be reported first to trial collaborators. The main report will be drafted by the WCTU CERM Trial team and the final version will be agreed by the wider Trial Management Group and submitted to the NIHR-EME Programme for approval before submission for publication.

The proposed trial will determine if a pre-pregnancy course of doxycycline in women with CE prevents miscarriage. If this is the case, implementation into clinical practise will be rapid as the diagnosis is based on endometrial biopsy, which is a routine outpatient procedure, the intervention (doxycycline) is inexpensive, widely used and safe antibiotic and there are currently few effective interventions to prevent miscarriage.²³ The trial will also determine the effects of doxycycline on the microbiome, and its effect on decidualisation and pregnancy outcome.

The results will be available to women, their partners, health care professionals and policy makers via the Tommy's website (<https://www.tommys.org>), social media, publications in open access journals, clinical practice guidelines (e.g. Royal College of Obstetricians and Gynaecologists, European Society of Human Reproduction and Endocrinology, National Institute for Health and Care Excellence (NICE)), conference presentations and via a trial webpage to be hosted on Warwick Medical School (<https://warwick.ac.uk/cerm>).

The trial will be reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines (www.consort-statement.org).³⁷ Authorship of all trial publications will be agreed in accordance with the WCTU SOP 22 'Publication and Dissemination'.

Links to all findings, reports, publications and events will be available via the trial website (<https://warwick.ac.uk/cerm>).

18. REFERENCES

1. Prior M, Bagness C, Brewin J, et al. Priorities for research in miscarriage: a priority setting partnership between people affected by miscarriage and professionals following the James Lind Alliance methodology. *BMJ Open* 2017;7(8) doi: 10.1136/bmjopen-2017-016571
2. Greenwood SM, Moran JJ. Chronic endometritis: Morphologic and clinical observations. *Obstetrics and Gynecology* 1981;58:176-84.
3. Wijdenes J, Vooijs WC, Clément C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. *British Journal of Haematology* 1996;94(2):318-23. doi: doi:10.1046/j.1365-2141.1996.d01-1811.x
4. Chen Y-q, Fang R-l, Luo Y-n, et al. Analysis of the diagnostic value of CD138 for chronic endometritis, the risk factors for the pathogenesis of chronic endometritis and the effect of chronic endometritis on pregnancy: a cohort study. *BMC Women's Health* 2016;16(1):60. doi: 10.1186/s12905-016-0341-3
5. Kasius JC, Broekmans FJM, Sie-Go DMDS, et al. The reliability of the histological diagnosis of endometritis in asymptomatic IVF cases: a multicenter observer study. *Human Reproduction* 2012;27(1):153-58. doi: 10.1093/humrep/der341
6. Kitaya K, Yasuo T, Tada Y, et al. Current understanding of chronic endometritis. *Diagnostic Histopathology* 2013;19(7):231-37. doi: 10.1016/j.mpdhp.2013.06.006
7. Cicinelli E, De Ziegler D, Nicoletti R, et al. Chronic endometritis: correlation among hysteroscopic, histologic, and bacteriologic findings in a prospective trial with 2190 consecutive office hysteroscopies. *Fertility and Sterility* 2008;89(3):677-84. doi: 10.1016/j.fertnstert.2007.03.074
8. Fang R-L, Chen L-X, Shu W-S, et al. Barcoded sequencing reveals diverse intrauterine microbiomes in patients suffering with endometrial polyps. *American Journal of Translational Research* 2016;8(3):1581-92.
9. Kitaya K, Matsubayashi H, Takaya Y, et al. Live birth rate following oral antibiotic treatment for chronic endometritis in infertile women with repeated implantation failure. *American Journal of Reproductive Immunology* 2017;78(5):e12719-n/a. doi: 10.1111/aji.12719
10. van Oostrum N, De Sutter P, Meys J, et al. Risks associated with bacterial vaginosis in infertility patients: a systematic review and meta-analysis. *Human Reproduction* 2013;28(7):1809-15. doi: 10.1093/humrep/det096
11. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. *Best Practice & Research Clinical Obstetrics & Gynaecology* 2007;21(3):375-90. doi: <https://doi.org/10.1016/j.bpobgyn.2006.12.005>
12. McQueen DB, Bernardi LA, Stephenson MD. Chronic endometritis in women with recurrent early pregnancy loss and/or fetal demise. *Fertility and Sterility* 2014;101(4):1026-30. doi: 10.1016/j.fertnstert.2013.12.031
13. Cicinelli E, Matteo M, Tinelli R, et al. Prevalence of chronic endometritis in repeated unexplained implantation failure and the IVF success rate after antibiotic therapy. *Human Reproduction* 2015;30(2):323-30. doi: 10.1093/humrep/deu292
14. Johnston-MacAnanny EB, Hartnett J, Engmann LL, et al. Chronic endometritis is a frequent finding in women with recurrent implantation failure after in vitro

- fertilization. *Fertility and Sterility* 2010;93(2):437-41. doi: <https://doi.org/10.1016/j.fertnstert.2008.12.131>
15. Yang R, Du X, Wang Y, et al. The hysteroscopy and histological diagnosis and treatment value of chronic endometritis in recurrent implantation failure patients. *Archives of Gynecology and Obstetrics* 2014;289(6):1363-69. doi: 10.1007/s00404-013-3131-2
 16. McQueen DB, Perfetto CO, Hazard FK, et al. Pregnancy outcomes in women with chronic endometritis and recurrent pregnancy loss. *Fertility and Sterility* 2015;104(4):927-31. doi: 10.1016/j.fertnstert.2015.06.044
 17. Zervomanolakis I, Ott HW, Hadziomerovic D, et al. Physiology of Upward Transport in the Human Female Genital Tract. *Annals of the New York Academy of Sciences* 2007;1101(1):1-20. doi: doi:10.1196/annals.1389.032
 18. Ansbacher R, Boyson WA, Morris JA. Sterility of the uterine cavity. *American Journal of Obstetrics & Gynecology* 1967;99(3):394-96. doi: 10.1016/S0002-9378(16)34549-5
 19. Pfefferle PI, Renz H. The mucosal microbiome in shaping health and disease. *F1000Prime Reports* 2014;6:11. doi: 10.12703/P6-11
 20. Aagaard K, Ma J, MAntony K, et al. The Placenta Harbors a Unique Microbiome. *Science Translational Medicine* 2014;6(237):237ra65-37ra65. doi: 10.1126/scitranslmed.3008599
 21. Whiteside SA, Razvi H, Dave S, et al. The microbiome of the urinary tract—a role beyond infection. *Nature Reviews Urology* 2015;12:81. doi: 10.1038/nrrol.2014.361
 22. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. *Proceedings of the National Academy of Sciences of the United States of America* 2011;108(Suppl 1):4680-87. doi: 10.1073/pnas.1002611107
 23. Franasiak JM, Werner MD, Juneau CR, et al. Endometrial microbiome at the time of embryo transfer: next-generation sequencing of the 16S ribosomal subunit. *Journal of Assisted Reproduction and Genetics* 2016;33(1):129-36. doi: 10.1007/s10815-015-0614-z
 24. Moreno I, Codoñer FM, Vilella F, et al. Evidence that the endometrial microbiota has an effect on implantation success or failure. *American Journal of Obstetrics & Gynecology* 2016;215(6):684-703. doi: 10.1016/j.ajog.2016.09.075
 25. Kumar A, Kumar A. Hysteroscopic Markers in Chronic Endometritis. *Journal of Minimally Invasive Gynecology* 2017;24(7):1069-70. doi: <https://doi.org/10.1016/j.jmig.2017.02.007>
 26. Gellersen B, Brosens JJ. Cyclic Decidualization of the Human Endometrium in Reproductive Health and Failure. *Endocrine Reviews* 2014;35(6):851-905. doi: 10.1210/er.2014-1045
 27. Lucas ES, Dyer NP, Murakami K, et al. Loss of Endometrial Plasticity in Recurrent Pregnancy Loss. *Stem Cells* 2016;34(2):346-56. doi: 10.1002/stem.2222
 28. Salker MS, Nautiyal J, Steel JH, et al. Disordered IL-33/ST2 Activation in Decidualizing Stromal Cells Prolongs Uterine Receptivity in Women with Recurrent Pregnancy Loss. *PLOS ONE* 2012;7(12):e52252. doi: 10.1371/journal.pone.0052252
 29. Salker MS, Christian M, Steel JH, et al. Deregulation of the serum- and glucocorticoid-inducible kinase SGK1 in the endometrium causes reproductive failure. *Nat Med* 2011;17(11):1509-13. doi: 10.1038/nm.2498
 30. Miller EA, Beasley DE, Dunn RR, et al. Lactobacilli Dominance and Vaginal pH: Why Is the Human Vaginal Microbiome Unique? *Frontiers in Microbiology* 2016;7:1936. doi: 10.3389/fmicb.2016.01936

31. Di Caprio R, Lembo S, Di Costanzo L, et al. Anti-Inflammatory Properties of Low and High Doxycycline Doses: An In Vitro Study. *Mediators of Inflammation* 2015;2015:10. doi: 10.1155/2015/329418
32. Matteo M, Cicinelli E, Greco P, et al. Abnormal Pattern of Lymphocyte Subpopulations in the Endometrium of Infertile Women with Chronic Endometritis. *American Journal of Reproductive Immunology* 2009;61(5):322-29. doi: doi:10.1111/j.1600-0897.2009.00698.x
33. Wu D, Kimura F, Zheng L, et al. Chronic endometritis modifies decidualization in human endometrial stromal cells. *Reproductive Biology and Endocrinology* 2017;15:16. doi: 10.1186/s12958-017-0233-x
34. Cross R, Ling C, Day NPJ, et al. Revisiting doxycycline in pregnancy and early childhood – time to rebuild its reputation? *Expert Opinion on Drug Safety* 2016;15(3):367-82. doi: 10.1517/14740338.2016.1133584
35. Coomarasamy A, Williams H, Truchanowicz E, et al. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. *New England Journal of Medicine* 2015;373(22):2141-48. doi: 10.1056/NEJMoa1504927
36. Liu Y, Chen X, Huang J, et al. Comparison of the prevalence of chronic endometritis as determined by means of different diagnostic methods in women with and without reproductive failure. *Fertility and Sterility* 2018;109(5):832-39. doi: 10.1016/j.fertnstert.2018.01.022
37. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet* 2001;357(9263):1191-4. [published Online First: 2001/04/27]